Menu
 
Research menu
Jump to menu

Publications:  Prof Thomas Powles

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS et al.(2020). A Consensus Molecular Classification of Muscle-invasive Bladder Cancer[Formula presented]. European Urology vol. 77, (4) 420-433.
10.1016/j.eururo.2019.09.006
Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, Albert ML, Powles T et al.(2020). Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Annals of Oncology vol. 31, (4) 525-531.
10.1016/j.annonc.2020.01.006
Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS et al.(2020). Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434–5. European Urology vol. 77, (4) 436-438.
10.1016/j.eururo.2019.12.014
Powles T(2020). Treatment Choices for Front-line Metastatic Clear Cell Renal Cancer. European Urology vol. 77, (4) 454-456.
10.1016/j.eururo.2020.01.011
Gómez de Liaño Lista A, van Dijk N, de Velasco Oria de Rueda G, Necchi A, Lavaud P, Morales-Barrera R, Alonso Gordoa T, Maroto P et al.(2020). Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer[Formula presented]. European Urology vol. 77, (2) 269-276.
10.1016/j.eururo.2019.10.004
Witjes JA, Babjuk M, Bellmunt J, Maxim Bruins H, De Reijke TM, De Santis M, Gillessen S, James N et al.(2020). EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort<sup>†</sup>[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees. European Urology vol. 77, (2) 223-250.
10.1016/j.eururo.2019.09.035
Fernández-Pello S, Hora M, Kuusk T, Tahbaz R, Dabestani S, Abu-Ghanem Y, Albiges L, Giles RH et al.(2020). Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel. European urology oncology vol. 3, (1) 57-72.
10.1016/j.euo.2019.04.005
Donskov F, Motzer RJ, Voog E, Hovey E, Grüllich C, Nott LM, Cuff K, Gil T et al.(2020). Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. European Journal of Cancer vol. 126, 1-10.
10.1016/j.ejca.2019.10.032
Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, Harris C, Winterbottom A et al.(2020). Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. The Lancet
10.1016/S0140-6736(20)30415-3
Liu WK, Lam JM, Butters T, Grant M, Jackson-Spence F, Bex A, Powles T, Szabados B(2020). Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach. World Journal of Urology
10.1007/s00345-020-03107-0
Grant M, Szabados B, Kuusk T, Powles T, Bex A(2020). Cytoreductive nephrectomy: Does CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) change everything?. Current Opinion in Urology vol. 30, (1) 36-40.
10.1097/MOU.0000000000000696
Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA et al.(2020). Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. The Lancet Oncology vol. 21, (1) 105-120.
10.1016/S1470-2045(19)30668-0
Powles T, Walker J, Andrew Williams J, Bellmunt J(2020). The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. Cancer Treatment Reviews vol. 82,
10.1016/j.ctrv.2019.101925
Buckley HL, Collinson FJ, Ainsworth G, Poad H, Flanagan L, Katona E, Howard HC, Murden G et al. (2019). PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. BMC Cancer. vol. 19,
10.1186/s12885-019-6273-1
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF et al.(2019). Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nature Medicine vol. 25, (11) 1706-1714.
10.1038/s41591-019-0628-7
Horwich A, Babjuk M, Bellmunt J, Bruins HM, Reijke TMD, Santis MD, Gillessen S, James N et al.(2019). EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. Annals of oncology : official journal of the European Society for Medical Oncology vol. 30, (11) 1697-1727.
10.1093/annonc/mdz296
Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S et al.(2019). Erratum: Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) (Annals of oncology : official journal of the European Society for Medical Oncology (2018) 29 2 (361-369) PII: S0923-7534(20)32577-1). Annals of oncology : official journal of the European Society for Medical Oncology vol. 30, (11)
10.1093/annonc/mdz214
Flaifel A, Xie W, Braun DA, Ficial M, Bakouny Z, Nassar AH, Jennings RB, Escudier B et al.(2019). PD-L1 expression and clinical outcomes to cabozantinib, everolimus, and sunitinib in patients with metastatic renal cell carcinoma: Analysis of the randomized clinical trials Meteor and Cabosun. Clinical Cancer Research vol. 25, (20) 6080-6088.
10.1158/1078-0432.CCR-19-1135
Song D, Powles T, Shi L, Zhang L, Ingersoll MA, Lu YJ(2019). Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. Journal of Pathology vol. 249, (2) 151-165.
10.1002/path.5306
Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B et al.(2019). Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. The Lancet Oncology vol. 20, (10) 1370-1385.
10.1016/S1470-2045(19)30413-9
De Bruijn RE, Mulders P, Jewett MA, Wagstaff J, Van Thienen JV, Blank CU, Van Velthoven R, Wood L et al.(2019). Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME)(Figure presented.). European Urology vol. 76, (4) 437-440.
10.1016/j.eururo.2019.06.006
Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Plimack ER, Pal S, De Giorgi U et al.(2019). The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. Oncologist vol. 24, (10) 1348-1355.
10.1634/theoncologist.2018-0739
Martini A, Jia R, Ferket BS, Waingankar N, Plimack ER, Crabb SJ, Harshman LC, Yu EY et al.(2019). Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. Cancer vol. 125, (18) 3155-3163.
10.1002/cncr.32169
Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U et al.(2019). A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors. Oncologist vol. 24, (9) 1151-e817.
10.1634/theoncologist.2018-0749
Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T et al.(2019). Erratum to ‘Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma’ (European Journal of Cancer (2019) 108 (33–40), (S0959804918315399), (10.1016/j.ejca.2018.11.031)). European Journal of Cancer vol. 119, 200-201.
10.1016/j.ejca.2019.04.012
Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P et al.(2019). Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. European Urology Focus vol. 5, (5) 857-866.
10.1016/j.euf.2018.02.010
Grimm MO, Bex A, De Santis M, Ljungberg B, Catto JWF, Rouprêt M, Hussain SA, Bellmunt J et al.(2019). Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. European Urology vol. 76, (3) 368-380.
10.1016/j.eururo.2019.05.041
Alifrangis C, McGovern U, Freeman A, Powles T, Linch M(2019). Molecular and histopathology directed therapy for advanced bladder cancer. Nature Reviews Urology vol. 16, (8) 465-483.
10.1038/s41585-019-0208-0
Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, Kuczyk MA, Lam TB et al.(2019). Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. European Urology vol. 76, (2) 151-156.
10.1016/j.eururo.2019.05.022
Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M et al.(2019). Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. Cancer Cell vol. 36, (1) 35-50.e9.
10.1016/j.ccell.2019.05.013
Neves JB, Shepherd S, Cullen D, Powles T, Aitchison M, Tran MGB(2019). Performance and cost of a renal cancer specialist multidisciplinary team meeting: Results from 1500 discussions. Journal of Clinical Urology vol. 12, (4) 314-319.
10.1177/2051415819829309
Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Banna GL, De Giorgi U et al.(2019). Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. European Urology vol. 76, (1) 73-81.
10.1016/j.eururo.2019.03.015
Porta C, Cosmai L, Leibovich BC, Powles T, Gallieni M, Bex A(2019). The adjuvant treatment of kidney cancer: a multidisciplinary outlook. Nature Reviews Nephrology vol. 15, (7) 423-433.
10.1038/s41581-019-0131-x
Rini BI, Powles T(2019). Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. Reply. The New England journal of medicine vol. 380, (26)
10.1056/NEJMc1905518
Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM et al.(2019). Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. The Lancet vol. 393, (10189) 2404-2415.
10.1016/S0140-6736(19)30723-8
Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Montes SFP, Giles RH, Hofmann F et al.(2019). European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. European Urology vol. 75, (5) 799-810.
10.1016/j.eururo.2019.02.011
Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Barber LJ, Woolston A, Spain G, Von Loga K et al.(2019). CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. Journal for ImmunoTherapy of Cancer vol. 7, (1)
10.1186/s40425-019-0575-3
Lam JM, Liu WK, Powles T, Tang YZ, Szabados B(2019). Single-centre Experience of Patients with Metastatic Urothelial Cancer Treated with Chemotherapy Following Immune Checkpoint Inhibition. Eur Urol Oncol
10.1016/j.euo.2019.03.001
Vogel C, Ziegelmüller B, Ljungberg B, Bensalah K, Bex A, Canfield S, Giles RH, Hora M et al.(2019). Imaging in Suspected Renal-Cell Carcinoma: Systematic Review. Clinical Genitourinary Cancer vol. 17, (2) e345-e355.
10.1016/j.clgc.2018.07.024
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B et al.(2019). Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine vol. 380, (12) 1116-1127.
10.1056/NEJMoa1816714
Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM et al.(2019). Corrigendum re: “Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens” (European Urology (2018) 73(3) (462–468), (S0302283817310151) (10.1016/j.eururo.2017.11.023)). European Urology vol. 75, (3) e82-e83.
10.1016/j.eururo.2018.11.032
Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A et al.(2019). Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. European Urology Focus vol. 5, (2) 242-249.
10.1016/j.euf.2017.05.006
Grünwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M, Sternberg CN, Rha SY et al.(2019). Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: Study design and rationale. Future Oncology vol. 15, (9) 929-941.
10.2217/fon-2018-0745
van Dijk N, Funt SA, Blank CU, Powles T, Rosenberg JE, van der Heijden MS(2019). The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. European Urology vol. 75, (3) 435-444.
10.1016/j.eururo.2018.09.022
Bex A, Mulders P, Jewett M, Wagstaff J, Van Thienen JV, Blank CU, Van Velthoven R, Del Pilar Laguna M et al.(2019). Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncology vol. 5, (2) 164-170.
10.1001/jamaoncol.2018.5543
Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P et al.(2019). Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR). European Urology vol. 75, (2) 261-264.
10.1016/j.eururo.2018.10.007
Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T et al.(2019). Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. European Journal of Cancer vol. 108, 33-40.
10.1016/j.ejca.2018.11.031
Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T et al.(2019). SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. World Journal of Urology vol. 37, (1) 95-105.
10.1007/s00345-018-2486-1
Kuusk T, Szabados B, Liu WK, Powles T, Bex A(2019). Cytoreductive nephrectomy in the current treatment algorithm. Therapeutic Advances in Medical Oncology vol. 11,
10.1177/1758835919879026
Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P et al.(2019). Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). Scandinavian Journal of Urology vol. 53, (1) 14-20.
10.1080/21681805.2019.1588919
Hall PE, Shepherd STC, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S et al.(2019). Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. European Urology Focus
10.1016/j.euf.2019.01.010
de Velasco G, Bex A, Albiges L, Powles T, Rini BI, Motzer RJ, Heng DYC, Escudier B(2019). Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. European Urology Oncology
10.1016/j.euo.2019.06.022
Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, Karam JA, Mason RJ et al.(2019). Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. European Urology vol. 75, (1) 111-128.
10.1016/j.eururo.2018.09.016
Lalani AKA, McGregor BA, Albiges L, Choueiri TK, Motzer R, Powles T, Wood C, Bex A(2019). Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. European Urology vol. 75, (1) 100-110.
10.1016/j.eururo.2018.10.010
Powles T, Rini B(2018). Novel agents and drug development needs in advanced clear cell renal cancer. Journal of Clinical Oncology vol. 36, (36) 3639-3644.
10.1200/JCO.2018.79.2655
Bex A, Albiges L, Staehler M, Bensalah K, Giles RH, Dabestani S, Hofmann F, Hora M et al.(2018). A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. European Urology vol. 74, (6) 849-851.
10.1016/j.eururo.2018.08.029
McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW et al.(2018). Erratum to: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (Nature Medicine, (2018), 24, 6, (749-757), 10.1038/s41591-018-0053-3). Nature Medicine vol. 24, (12)
10.1038/s41591-018-0235-z
Sonpavde GP, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, Crabb SJ, Bellmunt J et al.(2018). Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. Journal of Urology vol. 200, (6) 1207-1214.
10.1016/j.juro.2018.07.035
Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G et al.(2018). Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. European Urology Focus vol. 4, (6) 937-945.
10.1016/j.euf.2017.03.011
Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M et al.(2018). Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. European Urology vol. 74, (6) 805-809.
10.1016/j.eururo.2018.08.008
Bex A, Powles T, Haanen J(2018). To the editor. New England Journal of Medicine vol. 379, (19) 1877-1878.
10.1056/NEJMc1811532
Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, Harshman LC, Quinn DI et al.(2018). Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis [Figure presented]. European Urology vol. 74, (5) 611-620.
10.1016/j.eururo.2018.05.002
Tshuma N, Glynn N, Evanson J, Powles T, Drake WM(2018). Hypothalamitis and severe hypothalamic dysfunction associated with anti–programmed cell death ligand 1 antibody treatment. European Journal of Cancer vol. 104, 247-249.
10.1016/j.ejca.2018.09.016
Powles T(2018). Re: Nivolumab plus Ipilimumab Versus Sunitinib in Advanced Renal-cell Carcinoma. European Urology vol. 74, (5) 679-680.
10.1016/j.eururo.2018.07.019
Mansukhani S, Barber LJ, Kleftogiannis D, Moorcraft SY, Davidson M, Woolston A, Proszek PZ, Griffiths B et al.(2018). Ultra-Sensitive mutation detection and genome-wide DNA copy number reconstruction by error- corrected circulating tumor DNA sequencing. Clinical Chemistry vol. 64, (11) 1626-1635.
10.1373/clinchem.2018.289629
Wong YNS, Joshi K, Khetrapal P, Ismail M, Reading JL, Sunderland MW, Georgiou A, Furness AJS et al.(2018). Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. Journal of Experimental Medicine vol. 215, (11) 2748-2759.
10.1084/jem.20181003
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55768
Castellano D, Duran I, Rodríguez-Vida A, Crabb SJ, van der Heijden MS, Font Pous A, Gravis G, Anido Herranz U et al.(2018). A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS). Annals of oncology : official journal of the European Society for Medical Oncology vol. 29,
10.1093/annonc/mdy283.108
Galsky MD, Banchereau R, Kadel EE, Ramirez-Montagut T, Mariathasan S, Thåström A, Rosenberg J, Powles T et al.(2018). Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC). Annals of oncology : official journal of the European Society for Medical Oncology vol. 29,
10.1093/annonc/mdy283.111
Powles T, Morrison L(2018). Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma. Nature Reviews Urology vol. 15, (10) 585-587.
10.1038/s41585-018-0056-3
Gomez de Liano Lista A, Venugopal B, Fife K, Symeonides S, Vasudev NS, Rudman SM, Vohra S, Khasati L et al. (2018). Cabozantinib in metastatic renal cell carcinoma (mRCC): Data from UK expanded access program (EAP). Annals of oncology : official journal of the European Society for Medical Oncology. vol. 29,
10.1093/annonc/mdy283.102
Rini BI, Tannir NM, Escudier B, McDermott DF, Grimm MO, Porta C, Powles T, Kollmannsberger CK et al.(2018). Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214. Annals of oncology : official journal of the European Society for Medical Oncology vol. 29, viii309-viii310.
10.1093/annonc/mdy283.084
Petrylak DP, Rosenberg J, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner E, Melhem-Bertrandt A et al.(2018). EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC). Annals of oncology : official journal of the European Society for Medical Oncology vol. 29,
10.1093/annonc/mdy283.131
Rini BI, Huseni M, Atkins MB, McDermott DF, Powles TB, Escudier B, Banchereau R, Liu LF et al. (2018). Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC). Annals of oncology : official journal of the European Society for Medical Oncology. vol. 29, viii724-viii725.
10.1093/annonc/mdy424.037
Choueiri TK, Flaifel A, Xie W, Braun D, Ficial M, Jennings R, Nassar A, Escudier B et al. (2018). PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials. Annals of oncology : official journal of the European Society for Medical Oncology. vol. 29,
10.1093/annonc/mdy424.040
Collinson F, Brown S, Buckley H, Ainsworth G, Howard H, Poad H, Carr G, Banks RE et al.(2018). PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology vol. 29,
10.1093/annonc/mdy283.140
Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, Lim L, Powles T et al.(2018). Rituximab in the treatment of pembrolizumab-induced myasthenia gravis. European Journal of Cancer vol. 102, 49-51.
10.1016/j.ejca.2018.07.125
Suarez C, Choueiri TK, McDermott DF, Escudier B, Atkins MB, Powles TB, Rini BI, Motzer RJ et al. (2018). Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151. Annals of oncology : official journal of the European Society for Medical Oncology. vol. 29,
10.1093/annonc/mdy283.082
McDermott DF, Rini BI, Motzer RJ, Tannir NM, Escudier B, Kollmannsberger CK, Hammers HJ, Porta C et al. (2018). Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis. Annals of oncology : official journal of the European Society for Medical Oncology. vol. 29,
10.1093/annonc/mdy283.083
Powles T, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, Gurney H, Rha SY et al.(2018). Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. British Journal of Cancer vol. 119, (6) 663-669.
10.1038/s41416-018-0164-0
Powles T(2018). Choosing Front-line Treatment for Metastatic Renal Cancer: Which Data Are Meaningful?. European Urology vol. 74, (3) 322-323.
10.1016/j.eururo.2018.05.001
Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM(2018). Role of Checkpoint Inhibition in Localized Bladder Cancer. European Urology Oncology vol. 1, (3) 190-198.
10.1016/j.euo.2018.05.002
Barata PC, De Liano AG, Mendiratta P, Crolley V, Szabados B, Morrison L, Wood L, Allman K et al.(2018). The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. British Journal of Cancer vol. 119, (2) 160-163.
10.1038/s41416-018-0104-z
McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW et al.(2018). Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine vol. 24, (6) 749-757.
10.1038/s41591-018-0053-3
Motzer RJ, Escudier B, Powles T, Scheffold C, Choueiri TK(2018). Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. British Journal of Cancer vol. 118, (9) 1176-1178.
10.1038/s41416-018-0061-6
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P et al.(2018). Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. New England Journal of Medicine vol. 378, (14) 1277-1290.
10.1056/NEJMoa1712126
Boustani J, Bertaut A, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Recine F, Harshman LC et al.(2018). Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Acta Oncologica vol. 57, (4) 491-497.
10.1080/0284186X.2017.1369565
Powles T, Necchi A, Rosen G, Hariharan S, Apolo AB(2018). Anti–Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development. Clinical Genitourinary Cancer vol. 16, (2) 117-129.
10.1016/j.clgc.2017.11.002
Petrylak DP, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales-Barrera R, Burris HA, Kim JW et al.(2018). Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer long-term outcomes from a phase 1 study. JAMA Oncology vol. 4, (4) 537-544.
10.1001/jamaoncol.2017.5440
Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S et al.(2018). Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. Clinical Genitourinary Cancer vol. 16, (2) e483-e490.
10.1016/j.clgc.2017.10.012
Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D et al.(2018). Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. The Lancet Oncology vol. 19, (4) 451-460.
10.1016/S1470-2045(18)30107-4
Escudier B, Powles T, Motzer RJ, Olencki T, Frontera OA, Oudard S, Rolland F, Tomczak P et al.(2018). Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial. Journal of Clinical Oncology vol. 36, (8) 765-772.
10.1200/JCO.2017.74.7352
Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC et al.(2018). Quality of life outcomes for cabozantinib versus everolimus in patients with metastatic renal cell carcinoma: METEOR phase III randomized trial. Journal of Clinical Oncology vol. 36, (8) 757-764.
10.1200/JCO.2017.75.2170
Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM et al.(2018). Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. European Urology vol. 73, (3) 462-468.
10.1016/j.eururo.2017.11.023
Powles T, Albiges L, Staehler M, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M et al.(2018). Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. European Urology vol. 73, (3) 311-315.
10.1016/j.eururo.2017.11.016
Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM et al.(2018). Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. The Lancet vol. 391, (10122) 748-757.
10.1016/S0140-6736(17)33297-X
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE, Koeppen H et al.(2018). TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature vol. 554, (7693) 544-548.
10.1038/nature25501
Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S et al.(2018). Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: A Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Annals of Oncology vol. 29, (2) 361-369.
10.1093/annonc/mdx692
Szabados B, van Dijk N, Tang YZ, van der Heijden MS, Wimalasingham A, Gomez de Liano A, Chowdhury S, Hughes S et al.(2018). Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. European Urology vol. 73, (2) 149-152.
10.1016/j.eururo.2017.08.022
Ramos JD, Wingate JT, Gulati R, Plimack ER, Harshman LC, Powles T, Crabb SJ, Niegisch G et al.(2018). Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. Clinical Genitourinary Cancer vol. 16, (1) e161-e167.
10.1016/j.clgc.2017.08.001
Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G et al.(2018). ESMO consensus conference on testicular germ cell cancer: Diagnosis, treatment and follow-up. Annals of Oncology vol. 29, (8) 1658-1686.
10.1093/annonc/mdy217
Stephen Hodi F, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, Powles T, Smith D et al.(2018). Immune-modified response evaluation criteria in solid tumors (imrecist): Refining guidelines to assess the clinical benefit of cancer immunotherapy. Journal of Clinical Oncology vol. 36, (9) 850-858.
10.1200/JCO.2017.75.1644
Bene GD, Calabrò F, Giannarelli D, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK et al.(2018). Neoadjuvant vs. Adjuvant chemotherapy in muscle invasive bladder cancer (MIBC): Analysis from the RISC database. Frontiers in Oncology vol. 8, (NOV)
10.3389/fonc.2018.00463
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Edward E K, Koeppen H et al.(2017). TGF-β signalling attenuates tumour response to PD-L1 checkpoint blockade by contributing to retention of T cells in the peritumoural stroma. Annals of Oncology vol. 28,
10.1093/annonc/mdx760.001
Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S et al.(2017). Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. The Lancet vol. 390, (10109) 2266-2277.
10.1016/S0140-6736(17)32365-6
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58990
Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM et al.(2017). First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. The Lancet Oncology vol. 18, (11) 1483-1492.
10.1016/S1470-2045(17)30616-2
Tandstad T, Kollmannsberger CK, Roth BJ, Jeldres C, Gillessen S, Fizazi K, Daneshmand S, Lowrance WT et al.(2017). Practice makes perfect: The rest of the story in testicular cancer as a model curable neoplasm. Journal of Clinical Oncology vol. 35, (31) 3525-3528.
10.1200/JCO.2017.73.4723
Powles T, Gómez de Liaño A, Ackerman C(2017). Reply to Pontus Eriksson, Gottfrid Sjödahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48–55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed: Protein Expression to Predict Outcome to Targeted Therapy in Bladder Cancer: Too Little, Too Late?. European Urology vol. 72, (5) e137-e138.
10.1016/j.eururo.2017.05.025
Paul J, Kelly C, Stobo J, Powles T(2017). Reply to M. Horiguchi et al. Journal of Clinical Oncology vol. 35, (29)
10.1200/JCO.2017.74.4292
Powles T, Smith K, Stenzl A, Bedke J(2017). Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. European Urology vol. 72, (4) 477-481.
10.1016/j.eururo.2017.03.047
Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DYC, Powles T, Frigault MM, Clark EA et al.(2017). Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer. Journal of Clinical Oncology vol. 35, (26) 2993-3001.
10.1200/JCO.2017.72.2967
Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Wong Y-N, Pal SK, De Giorgi U et al. (2017). Impact of cisplatin-based therapy on long-term survival in advanced urinary tract cancer (aUTC). A retrospective international study of invasive/advanced cancer of the urothelium (RISC). ANNALS OF ONCOLOGY. vol. 28,
Choueiri TK, Powles T, Zhang T, Quinn DI, Gschwend JE, Wan SS, Poehlein C (2017). KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC). ANNALS OF ONCOLOGY. vol. 28,
Powles T, Motzer RJ, George DJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Mai TH et al. (2017). Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc). ANNALS OF ONCOLOGY. vol. 28,
Necchi A, Pond GR, Pal SK, Agarwal N, Bowles D, Plimack E, Yu EY, Ladoire S et al. (2017). Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population. ANNALS OF ONCOLOGY. vol. 28,
Grivas P, Plimack E, Balar AV, Castellano D, O'Donnell PH, Bellmunt J, Powles T, Hahn N et al. (2017). Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status. ANNALS OF ONCOLOGY. vol. 28,
Powles T, Gschwend JE, Loriot Y, Bellmunt J, Geczi L, Vulsteke C, Abdelsalam M, Gafanov R et al. (2017). Pembrolizumab +/- chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial. ANNALS OF ONCOLOGY. vol. 28,
Petrylak DP, Chi KN, Drakaki A, Sternberg CN, de Wit R, Nishiyama H, Yu EY, Castellano D et al. (2017). RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma. ANNALS OF ONCOLOGY. vol. 28,
Lista AGDL, Necchi A, Lavaud P, Carles Galceran J, Castellano D, Ravaud A, Duran I, van Dijk N et al. (2017). Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective. ANNALS OF ONCOLOGY. vol. 28,
Badreldin W, Powles T, Menard L, Ho-Yen C, Kermorgant S (2017). Understanding and targeting Met signalling in bladder cancer. ANNALS OF ONCOLOGY. vol. 28,
Wong YNS, Joshi K, Khetrapal P, Ismail M, Linares J, Akarca AU, Reading JL, Furness A et al. (2017). Urine-derived lymphocytes (UDLs) as a non-invasive surrogate marker of tumour infiltrating lymphocytes (TILs) in patients with muscle invasive bladder cancer (MIBC). ANNALS OF ONCOLOGY. vol. 28,
Powles T, O'Donnell PH, Massard C, Arkenau H-T, Friedlander TW, Hoimes CJ, Lee JL, Ong M et al.(2017). Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol vol. 3, (9) e172411-e172411.
10.1001/jamaoncol.2017.2411
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58500
Powles T(2017). Interview with Thomas Powles: The use of durvalumab in urothelial cancer - The latest strides in immuno-oncology. Future Oncology vol. 13, (18) 1581-1583.
10.2217/fon-2017-0207
Lubbock ALR, Stewart GD, O'Mahony FC, Laird A, Mullen P, O'Donnell M, Powles T, Harrison DJ et al.(2017). Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: A case study in advanced kidney cancer. BMC Medicine vol. 15, (1)
10.1186/s12916-017-0874-9
Van Neste C, Laird A, O¿Mahony F, Van Criekinge W, Deforce D, Van Nieuwerburgh F, Powles T, Harrison DJ et al.(2017). Epigenetic sampling effects: nephrectomy modifies the clear cell renal cell cancer methylome. Cellular Oncology vol. 40, (3) 293-297.
10.1007/s13402-016-0313-5
Jones RJ, Hussain SA, Protheroe AS, Birtle A, Chakraborti P, Huddart RA, Jagdev S, Bahl A et al.(2017). Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. Journal of Clinical Oncology vol. 35, (16) 1770-1777.
10.1200/JCO.2016.70.7828
Kuusk T, Albiges L, Escudier B, Grivas N, Haanen J, Powles T, Bex A(2017). Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. Angiogenesis vol. 20, (2) 205-215.
10.1007/s10456-017-9550-0
Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M et al.(2017). Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma. European Urology vol. 71, (5) 719-722.
10.1016/j.eururo.2016.11.034
González-Billalabeitia E, Sepúlveda JM, Maroto P, Aparicio J, Arranz JA, Esteban E, Gironés R, López-Brea M et al.(2017). Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer. European Urology Focus vol. 3, (2-3) 280-286.
10.1016/j.euf.2016.07.002
Sonpavde G, Pond GR, Mullane S, Ramirez AA, Vogelzang NJ, Necchi A, Powles T, Bellmunt J (2017). Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy. BJU International. vol. 119, 579-584.
10.1111/bju.13674
Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE et al.(2017). A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. European Urology vol. 71, (3) 426-436.
10.1016/j.eururo.2016.11.020
Bellmunt J, Powles T, Vogelzang NJ(2017). A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. Cancer Treatment Reviews vol. 54, 58-67.
10.1016/j.ctrv.2017.01.007
Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J et al.(2017). Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). European Urology vol. 71, (2) 281-289.
10.1016/j.eururo.2016.09.042
BALKWILL F, Berlato C, Khan MN, Schioppa T, Thompson R, Maniati E, Montfort A, Jangani M et al.(2017). A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer. Journal of Clinical Investigation
10.1172/JCI82976
https://qmro.qmul.ac.uk/xmlui/handle/123456789/18188
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A et al.(2017). Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. The Lancet vol. 389, (10064) 67-76.
10.1016/S0140-6736(16)32455-2
Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U et al.(2017). Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. Cancer Medicine vol. 6, (1) 186-194.
10.1002/cam4.986
Stewart GD, De Santis M, Escudier B, Powles T, Sonpavde G(2016). Immunotherapy for Renal Cancer: Sequencing and Combinations. European Urology Focus vol. 2, (6) 582-588.
10.1016/j.euf.2017.04.002
Bex A, Ljungberg B, van Poppel H, Powles T(2016). The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016. European Urology vol. 70, (6) 901-905.
10.1016/j.eururo.2016.07.005
Crusz SM, Tang YZ, Sarker SJ, Prevoo W, Kiyani I, Beltran L, Peters J, Sahdev A et al.(2016). Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma. BMC Medicine vol. 14, (1) 185-185.
10.1186/s12916-016-0729-9
https://qmro.qmul.ac.uk/xmlui/handle/123456789/18456
Powles THOMAS, Huddart RA, Elliott T, SARKER S-J, Ackerman CHARLOTTE, Jones R, Hussaine S, Crabb S et al.(2016). A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients. Journal of Clinical Oncology
10.1200/JCO.2015.66.3468
https://qmro.qmul.ac.uk/xmlui/handle/123456789/18322
Powles T, Grivas P, Aragon-Ching JB, Faroun Y, Kessler ER, Tomita Y, Chakrabarti D, Laliberte RJ et al.(2016). A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100). Annals of Oncology vol. 27,
10.1093/annonc/mdw373.69
Bamias A, Tzannis K, Liontos M, Crabb SJ, Harshman L, De Giorgi U, Bellmunt J, Wong YN et al. (2016). Adherence to cisplatin-based regimens prescription in “fit” patients fulfilling platinum eligibility criteria. Impact on outcomes: a retrospective international study of invasive/advanced cancer of the urothelium (RISC) analysis. Annals of Oncology. vol. 27,
10.1093/annonc/mdw373.27
Tannir N, Powles T, Motzer RJ, Rolland F, Gravis G, Staehler M, Rink M, Retz M et al. (2016). Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC). Annals of Oncology. vol. 27,
10.1093/annonc/mdw373.45
Loriot Y, Rosenberg JE, Powles TB, Necchi A, Hussain S, Morales R, Retz M, Niegisch G et al. (2016). Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study. Annals of Oncology. vol. 27,
10.1093/annonc/mdw373.11
Heng D, Park J, Signorovitch JE, Yang H, Song J, Weiss J, Dezzani L, Powles TB(2016). Clinical outcomes and dosing patterns of 2nd targeted therapy in metastatic renal carcinoma: a retrospective chart review in the EU. Annals of Oncology vol. 27,
10.1093/annonc/mdw373.54
Powles TB, Escudier B, de Souza P, Chowdhury S, Pook D, Harmenberg U, Basappa N, Geynisman D et al. (2016). Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial. Annals of Oncology. vol. 27,
10.1093/annonc/mdw373.41
Hessel C, Mangeshkar M, Motzer RJ, Escudier B, Powles TB, Schwab G, Choueiri TK (2016). Evaluation of the novel “trial within a trial” design of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). Annals of Oncology. vol. 27,
10.1093/annonc/mdw373.42
Bamias A, Tzannis K, Liontos M, Harshman L, Crabb SJ, Wong YN, Pal SK, Powles TB et al. (2016). Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advanced cancer of the urothelium (RISC) database. Annals of Oncology. vol. 27,
10.1093/annonc/mdw373.26
Balar A, Bellmunt J, O'Donnell PH, Castellano D, Grivas P, Vuky J, Powles T, Plimack ER et al. (2016). Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study. Annals of Oncology. vol. 27,
10.1093/annonc/mdw435.25
Cella D, Escudier B, Tannir N, Powles T, Donskov F, Peltola K, Schmidinger M, Heng D et al. (2016). Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC). Annals of Oncology. vol. 27,
10.1093/annonc/mdw373.43
Lardas M, Stewart F, Scrimgeour D, Hofmann F, Marconi L, Dabestani S, Bex A, Volpe A et al.(2016). Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus. European Urology vol. 70, (2) 265-280.
10.1016/j.eururo.2015.11.034
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11017
Powles T(2016). Where next in kidney cancer?. Annals of Oncology vol. 27, (8) 1376-1377.
10.1093/annonc/mdw247
Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F et al.(2016). Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. The Lancet Oncology vol. 17, (7) 917-927.
10.1016/S1470-2045(16)30107-3
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58982
Feber A, Worth DC, Chakravarthy A, de Winter P, Shah K, Arya M, Saqib M, Nigam R et al.(2016). CSN1 Somatic Mutations in Penile Squamous Cell Carcinoma. Cancer Research vol. 76, (16) 4720-4727.
10.1158/0008-5472.CAN-15-3134
https://qmro.qmul.ac.uk/xmlui/handle/123456789/56388
Powles T, Sarwar N, Stockdale A, Sarker S-J, Boleti E, Protheroe A, Jones R, Chowdhury S et al.(2016). Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer. JAMA Oncology vol. 2, (10) 1303-1309.
10.1001/jamaoncol.2016.1197
https://qmro.qmul.ac.uk/xmlui/handle/123456789/18441
Powles T, Lackner MR, Oudard S, Escudier B, Ralph C, Brown JE, Hawkins RE, Castellano D et al.(2016). Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology vol. 34, (14) 1660-1668.
10.1200/JCO.2015.64.8808
Rosenberg JE, Hoffman-Censits J, Powles T, Van Der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH et al.(2016). Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. The Lancet vol. 387, (10031) 1909-1920.
10.1016/S0140-6736(16)00561-4
Powles T, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E et al.(2016). A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology vol. 27, (5) 880-886.
10.1093/annonc/mdw014
Stewart GD, Powles T, Van Neste C, Meynert A, O'Mahony F, Laird A, Deforce D, Van Nieuwerburgh F et al.(2016). Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer. Oncotarget vol. 7, (18) 25241-25250.
10.18632/oncotarget.8308
Gulley JL, Mulders P, Albers P, Banchereau J, Bolla M, Pantel K, Powles T(2016). Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. OncoImmunology vol. 5, (4)
10.1080/2162402X.2015.1107698
Beaumont JL, Salsman JM, Diaz J, Deen KC, McCann L, Powles T, Hackshaw MD, Motzer RJ et al.(2016). Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. Cancer vol. 122, (7) 1108-1115.
10.1002/cncr.29888
Xu CF, Johnson T, Wang X, Carpenter C, Graves AP, Warren L, Xue Z, King KS et al.(2016). HLA-B∗57:01 confers susceptibility to pazopanib-associated liver injury in patients with cancer. Clinical Cancer Research vol. 22, (6) 1371-1377.
10.1158/1078-0432.CCR-15-2044
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11018
McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, Powderly JD, Infante JR et al.(2016). Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: Long-term safety, clinical activity, and immune correlates from a phase Ia study. Journal of Clinical Oncology vol. 34, (8) 833-842.
10.1200/JCO.2015.63.7421
Powles T, Wheater M, Din O, Geldart T, Boleti E, Stockdale A, Sundar S, Robinson A et al. (2016). A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer. European Urology. vol. 69, 450-456.
10.1016/j.eururo.2015.08.035
Feldman DR, Lorch A, Kramar A, Albany C, Einhorn LH, Giannatempo P, Necchi A, Flechon A et al.(2016). Brain metastases in patients with germ cell tumors: Prognostic factors and treatment options - An analysis from the Global Germ Cell Cancer Group. Journal of Clinical Oncology vol. 34, (4) 345-351.
10.1200/JCO.2015.62.7000
Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hofmann F et al.(2016). European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy. European Urology vol. 70, (5) 705-706.
10.1016/j.eururo.2016.06.009
Bridgeman VL, Wan E, Foo S, Nathan MR, Welti JC, Frentzas S, Vermeulen PB, Preece N et al.(2016). Preclinical evidence that trametinib enhances the response to antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma. Molecular Cancer Therapeutics vol. 15, (1) 172-183.
10.1158/1535-7163.MCT-15-0170
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11020
Bex A, Powles T, Karam JA(2016). Role of targeted therapy in combination with surgery in renal cell carcinoma. International Journal of Urology vol. 23, (1) 5-12.
10.1111/iju.12891
Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles R, Hofmann F et al.(2016). Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy. European Urology vol. 69, (1) 4-6.
10.1016/j.eururo.2015.10.017
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11019
Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F et al.(2015). Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: Results of the DATECAN project. Annals of Oncology vol. 26, (12) 2392-2398.
10.1093/annonc/mdv380
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11012
Kanu N, Grönroos E, Martinez P, Burrell RA, Yi Goh X, Bartkova J, Maya-Mendoza A, Mistrík M et al.(2015). SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. Oncogene vol. 34, (46) 5699-5708.
10.1038/onc.2015.24
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11014
Coleman R, Gray R, Powles T, Paterson A, Gnant M, Bergh J, Pritchard KI, Bliss J et al.(2015). Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials. The Lancet vol. 386, (10001) 1353-1361.
10.1016/S0140-6736(15)60908-4
Kurtoglu M, Davarpanah NN, Qin R, Powles T, Rosenberg JE, Apolo AB(2015). Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer vol. 13, (5) 410-420.
10.1016/j.clgc.2015.02.009
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11013
Olson TA, Murray MJ, Rodriguez-Galindo C, Nicholson JC, Billmire DF, Krailo MD, Dang HM, Amatruda JF et al.(2015). Pediatric and adolescent extracranial germ cell tumors: The road to collaboration. Journal of Clinical Oncology vol. 33, (27) 3018-3028.
10.1200/JCO.2014.60.5337
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11010
Stewart GD, O'Mahony FC, Laird A, Eory L, Lubbock ALR, Mackay A, Nanda J, O'Donnell M et al.(2015). Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer. Clinical Cancer Research vol. 21, (18) 4212-4223.
10.1158/1078-0432.CCR-15-0207
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11015
Rosenberg J, Petrylak D, Abidoye O, Van der Heijden MS, Hofman-Censits J, Necchi A, O'Donnell PH, Balmanoukian A et al. (2015). Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210). EUROPEAN JOURNAL OF CANCER. vol. 51, S720-S720.
10.1016/S0959-8049(16)31942-6
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11009
Choueiri T, Escudier B, Powles T, Mainwaring P, Rini B, Donskov F, Hammers H, Hutson T et al. (2015). Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial. EUROPEAN JOURNAL OF CANCER. vol. 51, S708-S709.
10.1016/S0959-8049(16)31927-X
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11011
Harshman L, Werner L, Wong YN, Yu E, Alva A, Crabb S, Powles T, Rosenberg J et al. (2015). Patterns and potential benefit of adjuvant chemotherapy for residual muscle invasive disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC). EUROPEAN JOURNAL OF CANCER. vol. 51, S518-S518.
10.1016/S0959-8049(16)31437-X
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11016
Marconi L, Dabestani S, Lam TB, Hofmann F, Stewart F, Norrie J, Bex A, Bensalah K et al.(2015). Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. EUROPEAN UROLOGY vol. 69, (4) 660-673.
10.1016/j.eururo.2015.07.072
Powles T(2015). Immune Checkpoint Inhibitors for Urologic Cancer: The Tip of the Iceberg?. European Urology vol. 68, (2) 280-282.
10.1016/j.eururo.2015.03.022
Feldman DR, Powles T(2015). Salvage high-dose chemotherapy for germ cell tumors. Urologic Oncology: Seminars and Original Investigations vol. 33, (8) 355-362.
10.1016/j.urolonc.2015.01.025
Mulders PF, De Santis M, Powles T, Fizazi K(2015). Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Cancer Immunology, Immunotherapy vol. 64, (6) 655-663.
10.1007/s00262-015-1707-3
Powles T, Bracarda S, Chen M, Norry E, Compton N, Heise M, Hutson T, Harter P et al.(2015). Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients. European Journal of Cancer vol. 51, (10) 1293-1302.
10.1016/j.ejca.2015.03.019
Petrylak DP, Powles T, Bellmunt J, Braiteh FS, Loriot Y, Zambrano CC, Burris HA, Kim JW et al. (2015). A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
10.1200/jco.2015.33.15_suppl.4501
Harshman LC, Werner L, Wong Y-N, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE et al. (2015). Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC). JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
10.1200/jco.2015.33.15_suppl.4524
De Santis M, Mulders P, Fizazi K, Gray TE, McCoy C, Stubbs A, Powles T (2015). First prospective, open-label, phase 2 study of sipuleucel-T (sip-T) in European men with metastatic, castration-resistant prostate cancer (mCRPC). JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
10.1200/jco.2015.33.15_suppl.e16015
Hussain SA, Jackson R, Shields A, Dickinson L, Cornford P, Jones RJ, Lester JF, Chester JD et al. (2015). Phase II randomised placebo controlled neoadjuvant chemotherapy study of nintedanib with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
10.1200/jco.2015.33.15_suppl.tps4574
Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T et al.(2015). EAU guidelines on renal cell carcinoma: 2014 update. European Urology vol. 67, (5) 913-924.
10.1016/j.eururo.2015.01.005
Powles T(2015). Immunotherapy: The development of immunotherapy in urothelial bladder cancer. Nature Reviews Clinical Oncology vol. 12, (4) 193-194.
10.1038/nrclinonc.2015.51
Kim JW, Bellmunt J, Powles T, Loriot Y, Vogelzang NJ, Zambrano CC, Burris HA, Teng S-LM et al. (2015). Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study. JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
10.1200/jco.2015.33.7_suppl.297
Choueiri TK, Figueroa DJ, Fay AP, Signoretti S, Liu Y, Gagnon R, Deen K, Carpenter C et al.(2015). Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: Results from COMPARZ, a randomized controlled trial. Clinical Cancer Research vol. 21, (5) 1071-1077.
10.1158/1078-0432.CCR-14-1993
Stewart G, Van Neste C, Meynert A, Semple C, O'Mahony F, Laird A, Mackay A, Trooskens G et al. (2015). Effect of sunitinib treatment on mutations and methylation in metastatic renal cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
10.1200/jco.2015.33.7_suppl.492
Ferguson J, McKibben M, Parker JS, Wallen E, Wood CG, Powles T, Rathmell K (2015). Evaluation of the effects of neoadjuvant pazopanib for renal cell carcinoma on intratumor genetic heterogeneity. JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
10.1200/jco.2015.33.7_suppl.425
Fitzpatrick A, Soosaipillai G, Wilson P, Powles T, Shamash J(2015). High Dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma in the VEGF Targeted Era. CLINICAL ONCOLOGY vol. 27, (3) E7-E8.
10.1016/j.clon.2014.11.022
Ramos J, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong Y-N, Bellmunt J, De Giorgi U et al. (2015). Impact of chemotherapy (CTX) on venous thromboembolism (VTE) and prognostic implications in patients with metastatic urinary tract tumors (UTT). JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
10.1200/jco.2015.33.7_suppl.318
Rodriguez-Vida A, Bianchini D, Van Hemelrijck M, Hughes S, Malik Z, Powles T, Bahl A, Rudman S et al.(2015). Is there an antiandrogen withdrawal syndrome with enzalutamide?. BJU International vol. 115, (3) 373-380.
10.1111/bju.12826
Albiges L, Choueiri T, Escudier B, Galsky M, George D, Hofmann F, Lam T, Motzer R et al.(2015). A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. Eur Urol vol. 67, (1) 100-110.
10.1016/j.eururo.2014.04.006
Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE et al.(2015). Cabozantinib versus everolimus in advanced renal-cell carcinoma. New England Journal of Medicine vol. 373, (19) 1814-1823.
10.1056/NEJMoa1510016
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T et al.(2015). Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer vol. 121, (15) 2586-2593.
10.1002/cncr.29387
Gurung PMS, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, Tan WS, Feber A, Crabb SJ et al.(2015). Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer. International Journal of Cancer vol. 136, (3) 709-720.
10.1002/ijc.29022
Kollmannsberger C, Tandstad T, Bedard PL, Cohn-Cedermark G, Chung PW, Jewett MA, Powles T, Warde PR et al.(2015). Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. Journal of Clinical Oncology vol. 33, (1) 51-57.
10.1200/JCO.2014.56.2116
Mather SJ, Nock BA, Maina T, Gibson V, Ellison D, Murray I, Sobnack R, Colebrook S et al.(2014). GRP receptor imaging of prostate cancer using [(99m)Tc]Demobesin 4: a first-in-man study. Mol Imaging Biol vol. 16, (6) 888-895.
10.1007/s11307-014-0754-z
Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA et al.(2014). MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature vol. 515, (7528) 558-562.
10.1038/nature13904
Escudier B, Porta C, Powles T, Eisen T, Sternberg CN, Mehmud F, Cella D(2014). Reply to S. Barni et Al and M. Sun et Al. J Clin Oncol vol. 32, (33) 3783-3784.
10.1200/JCO.2014.57.9219
Stewart GD, O'Mahony FC, Laird A, Rashid S, Martin SA, Eory L, Lubbock ALR, Nanda J et al.(2014). Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. Eur Urol vol. 66, (5) 956-963.
10.1016/j.eururo.2014.04.007
Choueiri TK, Escudier B, Pal SK, Jonasch E, Heng D, Powles T, Arkenau HT, Clark E et al. (2014). cMet: Proof-of-concept clinical trial with volitinib in patients with advanced papillary renal cell cancer (PRCC). EUROPEAN JOURNAL OF CANCER. vol. 50, 126-127.
10.1016/S0959-8049(14)70521-0
Ghazaly E, Perry J, Kitromilidou C, Powles T, Joel S(2014). Development and validation of an ultra-high performance LC-MS/MS assay for intracellular SN-38 in human solid tumour cell lines: comparison with a validated HPLC-fluorescence method. J Chromatogr B Analyt Technol Biomed Life Sci vol. 969, 213-218.
10.1016/j.jchromb.2014.08.024
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9727
Berlato C, Kahn MN, Schioppa T, Thompson R, Maniati E, Canosa M, Kulbe H, Sheldon C et al. (2014). Antagonists of the chemokine receptor CCR4 reverse the tumor-promoting microenvironment of renal cancer. CANCER RESEARCH. vol. 74,
10.1158/1538-7445.AM2014-1076
McDermott DF, Kluger HM, Sosman JA, Infante JR, Soria J-C, Hamid O, Delord J-P, Fasso M et al. (2014). Immune correlates and long-term follow-up of a Phase Ia study of MPDL3280A, an engineered PD-L1 antibody, in patients with metastatic renal cell carcinoma (mRCC). BJU INTERNATIONAL. vol. 114, 12-12.
Powles T, Hawkins R, Ralph C, Larkin J, Jones RJ, Chowdhury S, Boleti E, Fife K et al. (2014). A RANDOMISED PHASE II STUDY OF CEDIRANIB WITH OR WITHOUT SRC INHIBITION (SARACATINIB) IN METASTATIC CLEAR CELL RENAL CANCER (RCC) PATIENTS RESISTANT TO VEGF TARGETED THERAPY. ANNALS OF ONCOLOGY. vol. 25,
10.1093/annonc/mdu438.25
Powles T, Foreshew S-JS, Shamash J, Sarwar N, Crabb S, Sahdev A, Nixon J, Lim L et al.(2014). A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer. Eur J Cancer vol. 50, (12) 2057-2064.
10.1016/j.ejca.2014.04.021
Powles T, Davies R, Rini B(2014). Mammalian target of rapamycin inhibitors: the beginning of the end or the end of the beginning?. Eur Urol vol. 66, (2) 282-283.
10.1016/j.eururo.2013.09.026
Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME et al.(2014). Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity. CLINICAL GENITOURINARY CANCER vol. 12, (4) 262-269.
10.1016/j.clgc.2014.03.002
Stewart GD, Harrison DJ, Berney DM, Powles T(2014). The molecular biology of renal cancer: another piece of the puzzle. Eur Urol vol. 66, (1) 85-86.
10.1016/j.eururo.2014.03.004
Powles T, Oudard S, Escudier BJ, Brown JE, Hawkins RE, Castellano DE, Ravaud A, Staehler MD et al. (2014). A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT). JOURNAL OF CLINICAL ONCOLOGY. vol. 32,
10.1200/jco.2014.32.15_suppl.4525
Galsky MD, Harshman LC, Crabb SJ, Wong Y-N, Yu EY, Chowdhury S, Powles T, Pal SK et al. (2014). Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). JOURNAL OF CLINICAL ONCOLOGY. vol. 32,
10.1200/jco.2014.32.15_suppl.4512
Powles T, Vogelzang NJ, Fine GD, Eder JP, Braiteh FS, Loriot Y, Zambrano CC, Bellmunt J et al. (2014). Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). JOURNAL OF CLINICAL ONCOLOGY. vol. 32,
10.1200/jco.2014.32.15_suppl.5011
Beaumont JL, Diaz J, Deen KC, McCann L, Powles T, Hackshaw MD, Motzer RJ, Cella D (2014). Q-TWiST analysis of patients with metastatic renal cell carcinoma (mRCC) randomized to pazopanib (PAZ) or sunitinib (SUN). JOURNAL OF CLINICAL ONCOLOGY. vol. 32,
10.1200/jco.2014.32.15_suppl.4581
Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U et al.(2014). Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol vol. 32, (14) 1412-1418.
10.1200/JCO.2013.50.8267
Bex A, Fournier L, Lassau N, Mulders P, Nathan P, Oyen WJG, Powles T(2014). Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations. Eur Urol vol. 65, (4) 766-777.
10.1016/j.eururo.2013.11.031
Bharwani N, Miquel ME, Powles T, Dilks P, Shawyer A, Sahdev A, Wilson PD, Chowdhury S et al.(2014). Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma. Br J Cancer vol. 110, (3) 616-624.
10.1038/bjc.2013.790
Fitzpatrick AM, Greenwood M, Foreshew A, Nixon J, Sahdev A, Sarwar N, Lim L, Jones RJ et al. (2014). A phase Ib study exploring the combination of everolimus and dovitinib in VEGF-refractory clear cell renal cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 32,
10.1200/jco.2014.32.4_suppl.531
Kwan A, Shamash J, Powles T, Ansell W, Chowdhury S, Harland SJ, Lamont A, Wade R et al. (2014). An audit of adjuvant carboplatin in patients with stage I testicular seminoma (Anglian Germ Cell Cancer Group, UK). JOURNAL OF CLINICAL ONCOLOGY. vol. 32,
10.1200/jco.2014.32.4_suppl.366
Choueiri TK, Figueroa DJ, Liu Y, Gagnon RC, Deen KC, Carpenter C, Bartlett-Pandite AN, De Souza P et al. (2014). Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis. JOURNAL OF CLINICAL ONCOLOGY. vol. 32,
10.1200/jco.2014.32.4_suppl.416
Rodriguez-Vida A, Bianchini D, Hughes S, Lorente D, Crawley D, Van Hemelrijck M, Voskoboynik M, Chau NM et al. (2014). Is there an anti-androgen withdrawal effect with enzalutamide?. JOURNAL OF CLINICAL ONCOLOGY. vol. 32,
10.1200/jco.2014.32.4_suppl.200
Stewart G, Laird A, O'Mahony F, Eory L, Lubbock A, Nanda J, O'Donnell M, Mackay A et al. (2014). The effect of sunitinib on biomarkers and tumor heterogeneity in metastatic clear cell renal cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 32,
10.1200/jco.2014.32.4_suppl.408
Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TBL, Canfield SE, Staehler M, Powles T et al.(2014). Local treatments for metastases of renal cell carcinoma: A systematic review. The Lancet Oncology vol. 15, (12) e549-e561.
10.1016/S1470-2045(14)70235-9
Gurung PM, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, Tan WS, Feber A, Crabb SJ et al.(2014). Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer. International Journal of Cancer
10.1002/ijc.29022
Patel N, Arya M, Muneer A, Powles T, Sullivan M, Hines J, Kelly J(2014). Molecular aspects of upper tract urothelial carcinoma. Urol Oncol vol. 32, (1) 28.e11-28.e20.
10.1016/j.urolonc.2012.10.002
Sharpe K, Stewart GD, Mackay A, Van Neste C, Rofe C, Berney D, Kayani I, Bex A et al.(2013). The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clin Cancer Res vol. 19, (24) 6924-6934.
10.1158/1078-0432.CCR-13-1631
Choueiri TK, Escudier B, Powles T, Cella D, Lee Y, Laird DA, Scheffold C, Motzer RJ (2013). A phase 3 randomized study of cabozantinib (XL184) vs everolimus in subjects with clear cell renal cell carcinoma (METEOR). BJU INTERNATIONAL. vol. 112, 4-4.
Powles T, Kelly J(2013). Innovation: London Cancer-multidisciplinary approach to urological cancer. Nat Rev Clin Oncol vol. 10, (11) 609-610.
10.1038/nrclinonc.2013.179
Nichols CR, Roth B, Albers P, Einhorn LH, Foster R, Daneshmand S, Jewett M, Warde P et al.(2013). Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular Cancer. JOURNAL OF CLINICAL ONCOLOGY vol. 31, (28) 3490-3493.
10.1200/JCO.2012.47.6010
Crusz SM, Tang YZ, Sandev A, Kayani I, Harris L, Beltran L, Peters J, Swanton C et al. (2013). Heterogeneous response and progression patterns of renal cell carcinoma metastases in individual patients reveal intra-tumour heterogeneity of anti-angiogenic drug resistance. EUROPEAN JOURNAL OF CANCER. vol. 49, S641-S641.
Lim L, Mathias J, Lampron M, Fehr M, Gruenwald V, Khan M, Crabb S, Choueiri T et al. (2013). Liver toxicity in patients with metastatic renal cell carcinoma treated with pazopanib therapy. EUROPEAN JOURNAL OF CANCER. vol. 49, S660-S660.
Hodi FS, Powles T, Cassier P, Kowanetz M, Herbst RS, Soria JC, Mokatrin A, Stroh M et al. (2013). MPDL3280A (anti-PDL1): Clinical activity, safety and biomarkers of an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. EUROPEAN JOURNAL OF CANCER. vol. 49, S184-S184.
Mulder P, De Santis M, Fizazi K, Whitmore J, Sheikh N, McCoy C, Stubbs A, Powles T (2013). Preliminary product parameters from P11-1, a Phase 2, open-label trial of sipuleucel-T in European men with metastatic castrate-resistant prostate cancer (mCRPC). EUROPEAN JOURNAL OF CANCER. vol. 49, S696-S696.
Powles T (2013). The mechanism of resistance to targeted therapy. EUROPEAN JOURNAL OF CANCER. vol. 49, S38-S38.
Bhattacharyya M, Powles T, Mutsvangwa K, Wilson P, Oliver T, Shamash J(2013). A phase II study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of transitional cell carcinoma of the bladder. Urol Oncol vol. 31, (6) 878-882.
10.1016/j.urolonc.2011.07.015
Powles T, Kayani I, Sharpe K, Lim L, Peters J, Stewart GD, Berney D, Sahdev A et al.(2013). A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer. Ann Oncol vol. 24, (8) 2098-2103.
10.1093/annonc/mdt130
Rini BI, Powles T(2013). Biology and Treatment of Advanced Renal Cell Carcinoma: A Global Perspective. SEMINARS IN ONCOLOGY vol. 40, (4) 419-420.
10.1053/j.seminoncol.2013.05.003
Powles T, Bascoul-Mollevi C, Kramar A, Lorch A, Beyer J(2013). Prognostic impact of LDH levels in patients with relapsed/refractory seminoma. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY vol. 139, (8) 1311-1316.
10.1007/s00432-013-1442-0
Jamal-Hanjani M, Karpathakis A, Kwan A, Mazhar D, Ansell W, Shamash J, Harper P, Rudman S et al.(2013). Bone metastases in germ cell tumours: lessons learnt from a large retrospective study. BJU INTERNATIONAL vol. 112, (2) 176-181.
10.1111/bju.12218
Tookman L, Rashid S, Matakidou A, Phillips M, Wilson P, Ansell W, Jamal-Hanjani M, Chowdhury S et al.(2013). Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma. Acta Oncol vol. 52, (5) 987-993.
10.3109/0284186X.2012.714078
Galsky MD, Hahn NM, Powles T, Hellerstedt BA, Lerner SP, Gardner TA, Yu M, O'Rourke M et al.(2013). Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer. CLINICAL GENITOURINARY CANCER vol. 11, (2) 175-181.
10.1016/j.clgc.2012.10.001
Cho DC, Sosman JA, Sznol M, Gordon MS, Hollebecque A, Hamid O, McDermott DF, Delord J-P et al. (2013). Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). JOURNAL OF CLINICAL ONCOLOGY. vol. 31,
Powles T, Sarwar N, Stockdale A, Boleti E, Jones RJ, Protheroe A, Chowdhury S, Peters J et al. (2013). Pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer: A clinical and biomarker study. JOURNAL OF CLINICAL ONCOLOGY. vol. 31,
Galsky MD, Chowdhury S, Bellmunt J, Wong Y-N, Recine F, Pal SK, Moshier EL, Ladoire S et al. (2013). Treatment patterns and outcomes in "real world" patients (pts) with metastatic urothelial cancer (UC). JOURNAL OF CLINICAL ONCOLOGY. vol. 31,
Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E et al.(2013). Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. ANNALS OF ONCOLOGY vol. 24, (4) 878-888.
10.1093/annonc/mds579
Hardt A, Wilson P, Powles T, Shamash J(2013). The Outcome of Brain Metastases in Patients with Metastatic Germ Cell Tumours - Is Cranial Irradiation Necessary?. CLINICAL ONCOLOGY vol. 25, (4) E70-E71.
10.1016/j.clon.2012.12.015
Pal P, Roy A, Moore G, Muzslay M, Lee E, Alder S, Wilson P, Powles T et al.(2013). Keypad mobile phones are associated with a significant increased risk of microbial contamination compared to touch screen phones. Journal of Infection Prevention vol. 14, (2) 65-68.
10.1177/1757177413475903
Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A, Crabb S, Shamash J et al.(2013). The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-López. Eur J Cancer vol. 49, (4) 986-987.
10.1016/j.ejca.2012.10.010
Powles T, Sharpe K, Berney D, Kayani I, Doshi R, Stewart GD, Reynolds A, Bex A et al. (2013). Dynamic molecular changes with VEGF targeted therapy in metastatic clear cell renal cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 31,
10.1200/jco.2013.31.6_suppl.437
Powles T, Bex A(2013). Integration of surgery in metastatic renal cancer. Renal Cell Carcinoma: Clinical Management,
Kroon BK, de Bruijn R, Prevoo W, Horenblas S, Powles T, Bex A(2013). Probability of Downsizing Primary Tumors of Renal Cell Carcinoma by Targeted Therapies Is Related to Size at Presentation. UROLOGY vol. 81, (1) 111-115.
10.1016/j.urology.2012.09.014
Powles T, Crusz SM(2013). Sequencing systemic therapies in advanced RCC: is there a best strategy?. Am Soc Clin Oncol Educ Book
10.1200/EdBook_AM.2013.33.e172
Powles T, Kollmannsberger C, Feldman DR(2013). The conundrum of clinical trials in adult germ-cell tumours. Lancet Oncol vol. 14, (1) 14-15.
10.1016/S1470-2045(12)70561-2
O'Mahony FC, Nanda J, Laird A, Mullen P, Caldwell H, Overton IM, Eory L, O'Donnell M et al.(2013). The use of reverse phase protein arrays (RPPA) to explore protein expression variation within individual renal cell cancers. Journal of visualized experiments : JoVE (71)
10.3791/50221
Welti JC, Powles T, Foo S, Gourlaouen M, Preece N, Foster J, Frentzas S, Bird D et al.(2012). Contrasting effects of sunitinib within in vivo models of metastasis. ANGIOGENESIS vol. 15, (4) 623-641.
10.1007/s10456-012-9291-z
Powles T, Albers P(2012). Management of favorable-risk patients with metastatic renal cell carcinoma: when to start and when to stop targeted therapy. Clin Genitourin Cancer vol. 10, (4) 213-218.
10.1016/j.clgc.2012.06.002
Lim L, Powles T(2012). The management of low-stage non-seminomatous germ cell tumors. Oncology Reviews vol. 6, (2) 153-157.
10.4081/oncol.2012.e19
Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A, Crabb SJ, Shamash J et al.(2012). An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer. Eur J Cancer vol. 48, (17) 3171-3176.
10.1016/j.ejca.2012.05.022
Stewart GD, O'Mahony FC, Eory L, Nanda J, Laird A, O'Donnell M, Mullen P, Riddick ACP et al.(2012). Proteomic analysis of pre- and postsunitinib treated renal cancer tissue to assess tumour heterogeneity and differential protein expression. SCOTTISH MEDICAL JOURNAL vol. 57, (4) 245-246.
10.1258/smj.2012.012105
Powles TB, Jones RJ, Crabb S, Sarker S, Boleti E, Shamash J, Sarwar N, Chowdhury S (2012). A PHASE I DOSE ESCALATION STUDY INVESTIGATING DOVITINIB AND EVEROLMUS IN COMBINATION IN METASTATIC CLEAR CELL RENAL CANCER PATIENTS WHO HAVE PREVIOUSLY FAILED VEGF TARGETED THERAPY. ANNALS OF ONCOLOGY. vol. 23, 272-272.
Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP et al.(2012). A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. EUROPEAN UROLOGY vol. 62, (3) 523-533.
10.1016/j.eururo.2012.05.048
Powles T, Hutson TE(2012). Difficulty in predicting survival in metastatic renal cancer. Lancet Oncol vol. 13, (9) 859-860.
10.1016/S1470-2045(12)70318-2
Lim FL, Shamash J, Wilson P, Powles T (2012). LIVER TOXICITY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH PAZOPANIB THERAPY. ANNALS OF ONCOLOGY. vol. 23, 290-290.
Porta C, Tortora G, Linassier C, Papazisis K, Awada A, Berthold D, Maroto JP, Powles T et al.(2012). Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. MEDICAL ONCOLOGY vol. 29, (3) 1896-1907.
10.1007/s12032-011-0016-8
Birtle AJ, Lewis R, Chester J, Donovan J, Johnson M, Jones RJ, Kockelbergh R, Powles TB et al. (2012). PERI-OPERATIVE CHEMOTHERAPY OR SURVEILLANCE IN UPPER TRACT UROTHELIAL CANCER ( POUT - CRUK/11/027) - A NEW RANDOMISED CONTROLLED TRIAL TO DEFINE STANDARD POST-OPERATIVE MANAGEMENT. ANNALS OF ONCOLOGY. vol. 23, 292-292.
Sharpe K, Lu Y, Berney D, Rofe C, Powles T (2012). PRECLINICAL DATA INVESTIGATING THE USE OF SARACATINIB IN RENAL CELL CARCINOMA. ANNALS OF ONCOLOGY. vol. 23, 172-172.
Pons Valladares F, Choueiri TK, Hutson TE, Powles TB, Porta C, Bracarda S, Lampron ME, Cerbone L et al. (2012). SEQUENTIAL TARGETED THERAPY FOLLOWING PAZOPANIB (PZ) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CANCER (MRCC): EFFICACY AND TOXICITY. ANNALS OF ONCOLOGY. vol. 23, 278-278.
Porta C, Powles T(2012). Sequential therapy in metastatic renal cell carcinoma: what comes next?. MEDICAL ONCOLOGY vol. 29, (3) 1914-1915.
10.1007/s12032-011-0073-z
Blick C, Hall P, Pwint T, Al-Terkait F, Crew J, Powles T, Macaulay V, Munro N et al.(2012). Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. CANCER vol. 118, (16) 3920-3927.
10.1002/cncr.26675
Thillai K, Allan S, Powles T, Rudman S, Chowdhury S(2012). Neoadjuvant and adjuvant treatment of renal cell carcinoma. EXPERT REVIEW OF ANTICANCER THERAPY vol. 12, (6) 765-776.
10.1586/ERA.12.56
Powles T(2012). Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns. Clin Genitourin Cancer vol. 10, (2) 67-68.
10.1016/j.clgc.2012.04.001
Bex A, Powles T(2012). Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when. EXPERT REVIEW OF ANTICANCER THERAPY vol. 12, (6) 787-797.
10.1586/ERA.12.54
Rashid S, Lim L, Powles T(2012). Treatment of relapsed/refractory germ cell tumours: an equipoise between conventional and high dose therapy. Curr Treat Options Oncol vol. 13, (2) 201-211.
10.1007/s11864-012-0199-z
Bex A, Powles T, Blank CU, Chowdhury S, Horenblas S, Peters J, Boleti E, Haanen JBAG (2012). Outcome of rapid disease progression in the treatment break following cytoreductive nephrectomy (CN) after presurgical sunitinib in patients with primary metastatic renal cell carcinoma (RCC). JOURNAL OF CLINICAL ONCOLOGY. vol. 30,
Badreldin W, Chowdhury S, Harland SJ, Mazhar D, Powles T, Wilson P, Shamash J (2012). The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours: A non-cisplatin-based regimen. JOURNAL OF CLINICAL ONCOLOGY. vol. 30,
Shamash J, Jacob J, Agrawal S, Powles T, Mutsvangwa K, Wilson P, Stebbing J(2012). Whole blood stem cell reinfusion and escalated dose melphalan in castration-resistant prostate cancer: a phase 1 study. Clin Cancer Res vol. 18, (8) 2352-2359.
10.1158/1078-0432.CCR-11-3293
Kitromilidou C, Ghazaly E, Joel S, Powles T (2012). COMBINING HER1-4 TARGETED THERAPIES AND CHEMOTHERAPY IN BLADDER CANCER. ANNALS OF ONCOLOGY. vol. 23, 35-35.
Stewart GD, O'Mahony F, Eory L, Nanda J, Laird A, O'Donnell M, Mullen P, Riddick A et al.(2012). Proteomic analysis of pre- and post-sunitinib treated renal cancer tissue to assess tumor heterogeneity and differential protein expression. JOURNAL OF CLINICAL ONCOLOGY vol. 30, (5)
10.1200/jco.2012.30.5_suppl.388
Karpathakis A, Jamal-Hanjani M, Kwan A, Mazhar D, Rudman SM, Powles T, Shamash J, Chowdhury S(2012). Testicular germ cell tumors with bony metastases: Diagnosis, management, and outcomes (a case series). JOURNAL OF CLINICAL ONCOLOGY vol. 30, (5)
10.1200/jco.2012.30.5_suppl.343
Boleti E, Sarwar N, Jones RR, Chowdhury S, Crabb SJ, Shamash J, Peters J, Oades G et al.(2012). The safety and efficacy of pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer. JOURNAL OF CLINICAL ONCOLOGY vol. 30, (5)
10.1200/jco.2012.30.5_suppl.427
Doshi R, O'Donnel M, Bex A, Beltran L, Sahdev A, Peters J, Harrison DJ, Stewart GD et al. (2012). Renal Cell Carcinoma before and after Sunitinib Therapy. Morphological and Molecular Changes. LABORATORY INVESTIGATION. vol. 92, 201A-201A.
Gurung PMS, Williamson M, West C, Counsell N, Ahmed A, Benthani F, Feber A, Dewinter P et al.(2012). The tumour suppressor gene, AIMP3 sensitises bladder cancer to chemo/radiotherapy in vitro and is a prognostic marker for overall survival in patients treated with radiotherapy for muscle invasive disease. EUROPEAN UROLOGY SUPPLEMENTS vol. 11, (1) E669-U430.
Lim L, Powles T(2012). New prognostic models in metastatic renal cancer. Translational Andrology and Urology vol. 1, (3) 144-145.
10.3978/j.issn.2223-4683.2012.09.01
Shaw GL, Hussain M, Nair R, Bycroft J, Beltran L, Green JSA, Powles T, Peters JL(2012). Performing Cytoreductive Nephrectomy following Targeted Sunitinib Therapy for Metastatic Renal Cell Carcinoma: A Surgical Perspective. UROLOGIA INTERNATIONALIS vol. 89, (1) 83-88.
10.1159/000338057
Kalin M, Cima I, Schiess R, Fankhauser N, Powles T, Wild P, Templeton A, Cerny T et al.(2011). Novel Prognostic Markers in the Serum of Patients With Castration-Resistant Prostate Cancer Derived From Quantitative Analysis of the Pten Conditional Knockout Mouse Proteome. EUR UROL vol. 60, (6) 1235-1243.
10.1016/j.eururo.2011.06.038
Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, Van Hemelrijck M, McDermott DF et al.(2011). Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU INT vol. 108, (8) 1279-1283.
10.1111/j.1464-410X.2010.09990
Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, Van Hemelrijck M, McDermott DF et al.(2011). Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int vol. 108, (8) 1279-1283.
10.1111/j.1464-410X.2010.09990.x
Stephenson AJ, Aprikian AG, Gilligan TD, Oldenburg J, Powles T, Toner GC, Waters WB(2011). Management of Low-stage Nonseminomatous Germ Cell Tumors of Testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. UROLOGY vol. 78, (4) S444-S455.
10.1016/j.urology.2011.02.030
Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, Nathan P, Wilson P et al.(2011). Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res vol. 17, (18) 6021-6028.
10.1158/1078-0432.CCR-10-3309
Rimmer Y, Chester J, Joffe J, Stark D, Shamash J, Powles T, White J, Wason J et al.(2011). Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour. BRIT J CANCER vol. 105, (6) 766-772.
10.1038/bjc.2011.309
Bex A, Powles T(2011). Reply from Authors re: Simon P. Kim, R. Houston Thompson. Sunitinib Prior to Planned Cytoreductive Nephrectomy: Is This the New Litmus Test for Metastatic Renal Cell Carcinoma? Eur Urol 2011;60:455-6. EUR UROL vol. 60, (3) 456-457.
10.1016/j.eururo.2011.06.023
Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E et al.(2011). The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur Urol vol. 60, (3) 448-454.
10.1016/j.eururo.2011.05.028
Bex A, Powles T(2011). Reply to The sequence of cytoreductive nephrectomy: glass half empty or glass half full?. ANN ONCOL vol. 22, (7) 1691-1691.
10.1093/annonc/mdr274
Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U, Flechon A et al.(2011). Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database. J CLIN ONCOL vol. 29, (16) 2178-2184.
10.1200/JCO.2010.32.6678
Powles T(2011). Stage I nonseminomatous germ cell tumor of the testis: more questions than answers?. Hematol Oncol Clin North Am vol. 25, (3) 517-viii.
10.1016/j.hoc.2011.03.013
Lerner SP, Powles T, Hahn NM, Gardner T, Cheng L, Green J, Berney D, Taber D et al.(2011). A phase II trial of neoadjuvant cisplatin (C), gemcitabine (G), and sunitinib (S) in muscle-invasive urothelial carcinoma (miUC): Results from Hoosier Oncology Group GU07-123 trial. JOURNAL OF CLINICAL ONCOLOGY vol. 29, (15)
10.1200/jco.2011.29.15_suppl.e15173
Fizazi K, Powles T, George DJ, Poehlein CH(2011). A randomized, controlled phase III global trial comparing sipuleucel-T plus androgen deprivation therapy versus androgen deprivation therapy alone in men with metastatic androgen dependent (hormone sensitive) prostate cancer. JOURNAL OF CLINICAL ONCOLOGY vol. 29, (15)
10.1200/jco.2011.29.15_suppl.tps188
Chen GJ, Sonpavde G, Vale CL, Fisher D, Powles T, ABCMAC(2011). Association of progression-free survival (PFS) at 2 or 3 years with overall survival (OS) at 5 years for locally advanced bladder cancer (BC): Evaluation of individual patient data (IPD) from seven randomized trials comparing local therapy with or without neoadjuvant chemotherapy (NC). JOURNAL OF CLINICAL ONCOLOGY vol. 29, (15)
10.1200/jco.2011.29.15_suppl.4583
Shamash J, Jacob J, Powles T, Agrawal S, Mutsvangwa K, Saunders N, Wilson P, Stebbing J(2011). Melphalan and whole-blood stem cell reinfusion in castration-resistant prostate cancer (CRPC): A phase I/II study. JOURNAL OF CLINICAL ONCOLOGY vol. 29, (15)
10.1200/jco.2011.29.15_suppl.2573
Powles T, Mollevi C, Kramar A, Lorch A, Beyer J, IPFSG(2011). The prognostic significance of LDH levels in patients with relapsed/refractory seminoma and their predictive value of the new international prognostic score. JOURNAL OF CLINICAL ONCOLOGY vol. 29, (15)
10.1200/jco.2011.29.15_suppl.4584
Powles T, Kayani I, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N et al.(2011). The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Annals of Oncology vol. 22, (5) 1041-1047.
10.1093/annonc/mdq564
Stewart GD, O'Mahony FC, Powles T, Riddick ACP, Harrison DJ, Faratian D(2011). What can molecular pathology contribute to the management of renal cell carcinoma?. NAT REV UROL vol. 8, (5) 255-265.
10.1038/nrurol.2011.43
Powles T, Chowdhury S, Shamash J, Bazeos A, Gillessen S, Saunders N, Lim L, Sarwar N et al.(2011). Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib. Ann Oncol vol. 22, (4) 815-820.
10.1093/annonc/mdq469
Welti JC, Gourlaouen M, Powles T, Kudahetti SC, Wilson P, Berney DM, Reynolds AR(2011). Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene vol. 30, (10) 1183-1193.
10.1038/onc.2010.503
Hussain M, Nair R, Bycroft J, Green JSA, Powles T, Peters JL(2011). A COMPARISON OF OPEN RADICAL NEPHRECTOMY COMPLICATION RATES IN PATIENTS TREATED WITH NEOADJUVANT SUNITINIB FOR METASTATIC RENAL CELL CARCINOMA VERSUS NON-METASTATIC RENAL CELL CARCINOMA. EUR UROL SUPPL vol. 10, (2) 103-103.
10.1016/S1569-9056(11)60260-1
Blick C, Hall P, Pwint T, Munro N, Crew J, Powles T, Macaulay VM, Al-Terkait F et al.(2011). Accelerated MVAC as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. JOURNAL OF CLINICAL ONCOLOGY vol. 29, (7)
10.1200/jco.2011.29.7_suppl.235
Powles T, Chowdhury S, Avril N, Bomanji J, Shamash J, Sarwar N, Rockall A, Sahdev A et al.(2011). Sequential FDG-PET/CT as a surrogate marker of response to sunitinib in metastatic clear cell renal cancer. JOURNAL OF CLINICAL ONCOLOGY vol. 29, (7)
10.1200/jco.2011.29.7_suppl.301
Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A, Lim L, Hutson T(2011). Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer vol. 104, (5) 741-745.
10.1038/sj.bjc.6606061
Powles T, Blank C, Chowdhury S, Peters J, Haanen J, O'Brien T, Rockall AR, Sahdev AS et al.(2011). THE OUTCOME OF PATIENTS TREATED WITH UPFRONT SUNITINIB PRIOR TO NEPHRECTOMY IN METASTATIC CLEAR CELL RENAL CANCER. EUR UROL SUPPL vol. 10, (2) 102-103.
10.1016/S1569-9056(11)60259-5
Shamash J, Powles T, Sarker SJ, Protheroe A, Mithal N, Mills R, Beard R, Wilson P et al.(2011). A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol. BRIT J CANCER vol. 104, (4) 620-628.
10.1038/sj.bjc.6606102
https://qmro.qmul.ac.uk/xmlui/handle/123456789/10335
Feldman DR, Huddart R, Hall E, Beyer J, Powles T(2011). Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial. JOURNAL OF CANCER vol. 2, 374-377.
10.7150/jca.2.374
Powles T, Chowdhury S, Bower M, Saunders N, Lim L, Shamash J, Sarwar N, Sadev A et al.(2011). The Effect of Sunitinib on Immune Subsets in Metastatic Clear Cell Renal Cancer. UROL INT vol. 86, (1) 53-59.
10.1159/000319498
Perry J, Ghazaly E, Kitromilidou C, McGrowder EH, Joel S, Powles T(2010). A Synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP. Molecular Cancer Therapeutics vol. 9, (12)
10.1158/1535-7163.MCT-10-0673
Bex A, Jonasch E, Kirkali Z, Mejean A, Mulders P, Oudard S, Patard JJ, Powles T et al.(2010). Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials. EUR UROL vol. 58, (6) 819-828.
10.1016/j.eururo.2010.08.029
Lorch A, Beyer J, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Flechon A et al.(2010). Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. Journal of Clinical Oncology vol. 28, (33) 4906-4911.
10.1200/JCO.2009.26.8128
Gerlinger M, Wilson P, Powles T, Shamash J(2010). Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy. Eur J Cancer vol. 46, (16) 2913-2918.
10.1016/j.ejca.2010.07.004
Poffiri E, Miscoria M, Lim L, Shamash J, Chowdhury S, Powles T (2010). THE OUTCOME OF PATIENTS WHO FAIL SUNITINIB AND DO NOT HAVE ACCESS TO SUNITINIB THERAPY. ANNALS OF ONCOLOGY. vol. 21, 292-292.
Shamash J, Stebbing J, Sweeney C, Sonpavde G, Harland S, Dawkins G, Brock C, Abelman W et al.(2010). A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer. Cancer vol. 116, (15) 3595-3602.
10.1002/cncr.25194
Gillessen S, Powles T, Lim L, Wilson P, Shamash J(2010). Low-dose induction chemotherapy with Baby-BOP in patients with metastatic germ-cell tumours does not compromise outcome: a single-centre experience. Ann Oncol vol. 21, (8) 1589-1593.
10.1093/annonc/mdq019
Matakidou A, Mutsvangwa K, Ansell W, Lim L, Powles TB, Oliver RT, Shamash J(2010). Single-agent carboplatin AUC10 for metastatic seminoma with IGCCCG good prognosis disease; a feasibility study of the Orchid Clinical Trials Group. Ann Oncol vol. 21, (8) 1730-1731.
10.1093/annonc/mdq300
Powles T, Jones R, Chowdhury S, Shamash J, Mantle M, Lim L, Hutson T(2010). The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe?. BJU Int vol. 106, (4) 453-457.
10.1111/j.1464-410X.2010.09466.x
Noel EE, Yeste-Velasco M, Mao X, Perry J, Kudahetti SC, Li NF, Sharp S, Chaplin T et al.(2010). The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol vol. 176, (6) 2607-2615.
10.2353/ajpath.2010.090780
Avril N, Dambha F, Murray I, Shamash J, Powles T, Sahdev A(2010). The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers. Int J Urol vol. 17, (6) 501-511.
10.1111/j.1442-2042.2010.02509.x
Escudier BJ, Cella D, Gschwend JE, Powles T, Sternberg CN, Hodge R, Lau M, Neary M et al.(2010). A randomized double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment-naive locally advanced or metastatic renal cell carcinoma (mRCC). JOURNAL OF CLINICAL ONCOLOGY vol. 28, (15)
10.1200/jco.2010.28.15_suppl.tps237
Chowdhury S, O'Brien TS, Sarwar N, Shamash J, McGrath S, Agrawal S, Lim L, Rudman SM et al.(2010). The effect of sunitinib on immune parameters and haemopoetic stem cell markers in patients with untreated cleat cell renal cancer. JOURNAL OF CLINICAL ONCOLOGY vol. 28, (15)
10.1200/jco.2010.28.15_suppl.4620
Powles T, Kayani I, Blank CU, Chowdhury S, Horenblas S, Sarwar N, Nathan PD, Boleti E et al.(2010). The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. JOURNAL OF CLINICAL ONCOLOGY vol. 28, (15)
10.1200/jco.2010.28.15_suppl.4603
Bharwani N, Miquel M, Sahdev A, Powles T, Reznek R, Rockall A (2010). Diffusion-Weighted MRI in the Assessment of Tumor Response to Novel Targeted Therapies in Metastatic Renal Cell Carcinoma. AMERICAN JOURNAL OF ROENTGENOLOGY. vol. 194,
El-Hariry I, Powles T, Lau MR, Sternberg CN, Ravaud A, von der Maase H, Zantl N, Harper P et al.(2010). Amplification of epidermal growth factor receptor gene in renal cell carcinoma. EUR J CANCER vol. 46, (5) 859-862.
10.1016/j.ejca.2010.01.011
Chowdhury S, Harper P, Powles T(2010). Castration Refractory Prostate Cancer: Cinderella Finally Comes to the Ball. ONKOLOGIE vol. 33, (12) 655-656.
10.1159/000322635
Matakidou A, Mutsvangwa K, Ansell W, Powles T, Oliver T, Shamash J(2009). Single-agent Carboplatin AUC10 for Metastatic Seminoma with IGCCCG Good Prognosis Disease; a Feasibility Study of the Orchid Clinical Trials Group. CLIN ONCOL-UK vol. 21, (10) 800-800.
10.1016/j.clon.2009.10.010
Perry J, Powles T, Shamash J, Veerupillai A, McGrowder E, Noel E, Lu Y-J, Oliver T et al.(2009). The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines. Cancer Chemother Pharmacol vol. 64, (5) 925-933.
10.1007/s00280-009-0944-6
Murugaesu N, Powles T, Bestwick J, Oliver RTD, Shamash J(2009). Long-term follow-up of testicular cancer patients shows no predisposition to osteoporosis. Osteoporos Int vol. 20, (9) 1627-1630.
10.1007/s00198-008-0793-x
Josephs DH, Hutson TE, Pickering LM, Larkin JM, Choueiri TK, Patel TV, Mcdermott DF, Powles T et al. (2009). Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis. JOURNAL OF CLINICAL ONCOLOGY. vol. 27,
Hahn NM, Powles T, Sweeney CJ(2009). Development of novel agents for bladder cancer. Update on Cancer Therapeutics vol. 3, (4) 160-169.
10.1016/j.uct.2009.04.001
Nathan P, Wagstaff J, Porfiri E, Powles T, Eisen T(2009). UK guidelines for the systemic treatment of renal cell carcinoma. BRIT J HOSP MED vol. 70, (5) 284-286.
10.12968/hmed.2009.70.5.42228
Powles T, Robinson D, Stebbing J, Nelson M, Mandalia S, Moller H, Gazzard B, Bower M(2009). Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. HIV MED vol. 10, 4-4.
Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, Gazzard B, Bower M(2009). The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol vol. 20, (4) 775-779.
10.1093/annonc/mdn697
Gerlinger M, Wilson P, Powles T, Oliver RTD, Shamash J(2009). ESTABLISHED PROGNOSTIC MODELS FAIL TO PREDICT THE OUTCOME OF DOSE DENSE CHEMOTHERAPY FOR THE TREATMENT OF RECURRENT GERM CELL TUMOURS (GCTS). EUR UROL SUPPL vol. 8, (4) 358-358.
10.1016/S1569-9056(09)60936-2
Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, Mandelia S, Moller H et al.(2009). Highly Active Antiretroviral Therapy and the Incidence of Non-AIDS-Defining Cancers in People With HIV Infection. J CLIN ONCOL vol. 27, (6) 884-890.
10.1200/JCO.2008.19.6626
Stancliffe M, Powles T, Bower M(2009). HIV-related lung cancer in the age of HAART. Multidisciplinary Respiratory Medicine vol. 4, (3) 225-228.
Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM et al.(2009). The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer vol. 63, (1) 94-97.
10.1016/j.lungcan.2008.04.001
Nelson M, Powles T, Zeitlin A, Sen P, Scourfield A, Bower M, Gazzard B, Stebbing J(2009). Thyroid dysfunction and relationship to antiretroviral therapy in hiv-positive individuals in the HAART era. Journal of Acquired Immune Deficiency Syndromes vol. 50, (1) 113-114.
10.1097/QAI.0b013e31818ce835
Oliver T, Powles T, Nargund V, Berney D(2008). Spontaneous regression of renal cell carcinoma and the role of prognostic factors. Clinical Management of Renal Tumors,
Jones R, Nelson M, Bower M, Powles T, Mandalia S, Gazzard B, Stebbing J(2008). Triple-class antiretroviral agent resistance in a large cohort: Prevalence and clinical outcomes. ARCH INTERN MED vol. 168, (17) 1926-1927.
10.1001/archinte.168.17.1926
Gaughan EM, Dezube BJ, Aboulafia D, Bower M, Strebbing J, Powles T, Pantanowitz L(2008). Human immunodeficiency virus-associated renal cell carcinoma: A transatlantic case series. CLIN GENITOURIN CANC vol. 6, (2) 86-90.
10.3816/CGC.2008.n.013
Bazoes A, Bower M, Powles T(2008). Smoke and mirrors: HIV-related lung cancer. Curr Opin Oncol vol. 20, (5) 529-533.
10.1097/CCO.0b013e32830a4c99
Powles T, McFaul S, Stebbing J, Wilson P, Oliver T, Tranter N, Shamash J(2008). The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer. Onco Targets Ther vol. 1, 35-39.
10.2147/ott.s3590
Bower M, Collins S, Cottrill C, Cwynarski K, Montoto S, Nelson M, Nwokolo N, Powles T et al.(2008). British HIV Association guidelines for HIV-associated malignancies 2008. HIV MED vol. 9, (6) 336-388.
10.1111/j.1468-1293.2008.00608.x
Perry J, Nsubuga E, Joel S, Shamash J, El-Hariry I, Powles T(2008). A synergistic interaction between lapatinib and topoisomerase I inhibitors in cisplatin sensitive and resistant cancer cell lines. JOURNAL OF CLINICAL ONCOLOGY vol. 26, (15)
10.1200/jco.2008.26.15_suppl.14618
Gerlinger M, Wilson P, Powles T, Shamash J(2008). Non-castrate status at the end of chemotherapy for metastatic hormone-resistant prostate cancer (HRPC) correlates with a better overall survival. JOURNAL OF CLINICAL ONCOLOGY vol. 26, (15)
10.1200/jco.2008.26.15_suppl.16102
Bower M, Stebbing J, Tuthill MH, Krell J, Campbell V, Nelson M, Gazzard B, Powles T(2008). Recovery of cellular immunity following chemotherapy for AIDS related non Hodgkin's lymphoma. JOURNAL OF CLINICAL ONCOLOGY vol. 26, (15)
10.1200/jco.2008.26.15_suppl.8582
Bazeos A, Powles T, Stebbing J, Mandalia S, Bower M(2008). The increasing incidence of HIV-associated multicentric Castlemans disease. JOURNAL OF CLINICAL ONCOLOGY vol. 26, (15)
10.1200/jco.2008.26.15_suppl.7085
Stebbing J, Powles T, Mandalia S, Nelson M, Gazzard B, Bower M(2008). Use of antidepressants and risk of cancer in individuals infected with HIV. J CLIN ONCOL vol. 26, (14) 2305-2310.
10.1200/JCO.2007.15.9681
Bower M, Stebbing J, Tuthill M, Campbell V, Krell J, Holmes P, Ozzard A, Nelson M et al.(2008). Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma. BLOOD vol. 111, (8) 3986-3990.
10.1182/blood-2007-10-115659
Sonpavde G, Ross R, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Lerner SP et al.(2008). Novel agents for muscle-invasive and advanced urothelial cancer. BJU INT vol. 101, (8) 937-943.
10.1111/j.1464-410X.2007.07326.x
Macdonald DC, Nelson M, Bower M, Powles T(2008). Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. WORLD J GASTROENTERO vol. 14, (11) 1657-1663.
10.3748/wjg.14.1657
Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I et al.(2008). European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part I. EUR UROL vol. 53, (3) 478-496.
10.1016/j.eururo.2007.12.024
Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Alyaba F, Bamberg M, Bodrogi I et al.(2008). European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. EUR UROL vol. 53, (3) 497-513.
10.1016/j.eururo.2007.12.025
Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T(2008). The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. ANN ONCOL vol. 19, (3) 443-447.
10.1093/annonc/mdm540
Stebbing J, Powles T, Bower M(2008). AIDS-associated Kaposi's sarcoma associated with a low viral load and a high CD4 cell count. AIDS vol. 22, (4) 551-552.
10.1097/QAD.0b013e3282f4de5d
Shamash J, Davies A, Ansell W, Mcfaul S, Wilson P, Oliver T, Powles T(2008). A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. BRIT J CANCER vol. 98, (1) 22-24.
10.1038/sj.bjc.6604051
Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I et al.(2008). Corrigendum to: "European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer. European Urology vol. 54, (2)
10.1016/j.eururo.2008.03.017
Liu WM, Scott KA, Shamash J, Joel S, Powles TB(2008). Enhancing the in vitro cytotoxic activity of Delta(9)-tetrahydrocannabinol in leukemic cells through a combinatorial approach. LEUKEMIA LYMPHOMA vol. 49, (9) 1800-1809.
10.1080/10428190802239188
Berney DM, Warren AY, Verma M, Kudahetti S, Robson JM, Williams MW, Neal DE, Powles T et al.(2008). Malignant germ cell tumours in the elderly: a histopathological review of 50 cases in men aged 60 years or over. Mod Pathol vol. 21, (1) 54-59.
10.1038/modpathol.3800978
Waters L, Nelson M, Mandalia S, Bower M, Powles T, Gazzard B, Stebbing J(2008). The risks and incidence of K65R and L74V mutations and subsequent virologic responses. CLIN INFECT DIS vol. 46, (1) 96-100.
10.1086/523001
Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, Orkin C, Webb A et al.(2007). Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med vol. 147, (12) 836-839.
10.7326/0003-4819-147-12-200712180-00003
Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Berry WR et al.(2007). Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer vol. 110, (12) 2628-2639.
10.1002/cncr.23085
Powles T, Stebbing J, Montoto S, Nelson M, Gazzard B, Orkin C, Webb A, Bower M(2007). Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease [4]. Blood vol. 110, (12) 4132-4133.
10.1182/blood-2007-08-106187
Davies CL, Chinn R, Nelson M, Rasanesan M, Gazzard B, Powles T, Bower M, Stebbing J(2007). Outcome in AIDS-related systemic non-Hodgkin lymphoma and leptomeningeal disease is not predicted by a CT brain scan. AM J NEURORADIOL vol. 28, (10) 1988-1990.
10.3174/ajnr.A0718
Shamash J, Stebbing J, Powles T(2007). Germ-cell tumors. NEW ENGL J MED vol. 357, (17) 1771-1772.
10.1056/NEJMc072495
Shamash J, Powles T, Ansell W, Berney D, Stebbing J, Mutsvangwa K, Wilson P, Asterling S et al.(2007). Erratum: GAMEC - A new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours (British Journal of Cancer (2007) 97, (308-314) DOI: 10.1038/6603865). British Journal of Cancer vol. 97, (8)
10.1038/sj.bjc.6604041
Young AM, Powles T, Holmes P, Wang J, Nelson M, Anderson J, Bower MD, Brock CS(2007). An HIV-associated mediastinal germ cell tumour complicated by acute myeloid leukaemia. Journal of HIV Therapy vol. 12, (3) 68-71.
Bazeos A, Powles T, Stebbing J(2007). HIV-associated multicentric Castleman's disease: From case reports to evidence. Journal of HIV Therapy vol. 12, (3) 61-62.
Walters Z, Shamash J, Powles T(2007). Prostate cancer in HIV-positive individuals: what we know and what we don't. J HIV Ther vol. 12, (3) 66-67.
Stebbing J, Nathan B, Jones R, McKenna A, Powles T, Bower M, Holmes P, Gazzard B et al.(2007). Virological failure and subsequent resistance profiles in individuals exposed to atazanavir. AIDS vol. 21, (13) 1826-1828.
10.1097/QAD.0b013e3282742000
Shamash J, Powles T, Ansell W, Stebbing J, Mutsvangwa K, Wilson P, Asterling S, Liu S et al.(2007). GAMEC - a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours. BRIT J CANCER vol. 97, (3) 308-314.
10.1038/sj.bjc.6603865
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12053
Powles T, Murray I, Brock C, Oliver T, Avril N(2007). Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol vol. 51, (6) 1511-1520.
10.1016/j.eururo.2007.01.061
Stebbing J, Sanitt A, Teague A, Powles T, Nelson M, Gazzard B, Bower M(2007). Prognostic significance of immune subset measurement in individuals with AIDS-associated Kaposi's sarcoma. J CLIN ONCOL vol. 25, (16) 2230-2235.
10.1200/JCO.2007.10.7219
Shamash J, Powles T, Mutsvangwa K, Wilson P, Ansell W, Walsh E, Berney D, Stebbing J et al.(2007). A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours. ANN ONCOL vol. 18, (5) 925-930.
10.1093/annonc/mdm002
Powles T, Ell PJ(2007). Does PET imaging have a role in renal cancers after all?. LANCET ONCOL vol. 8, (4) 279-281.
10.1016/S1470-2045(07)70080-3
Stebbing J, Powles T(2007). Stress in the workplace amongst medical professionals. J POSTGRAD MED vol. 53, (2) 83-84.
10.4103/0022-3859.32202
Powles T, Savage PM, Stebbing J, Short D, Young A, Bower M, Pappin C, Schmid P et al.(2007). A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. BRIT J CANCER vol. 96, (5) 732-737.
10.1038/sj.bjc.6603608
Powles T, Perry J, Shamash J, Liu W, Oliver T, Joel S(2007). A comparison of the platinum analogues in bladder cancer cell lines. UROL INT vol. 79, (1) 67-72.
10.1159/000102917
Powles T, Young A, Sanitt A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al.(2006). Erratum: The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours (British Journal of Cancer (2006) 95, (1145-1147) DOI: 10.1038/sj.bjc.6603416). British Journal of Cancer vol. 95, (12)
10.1038/sj.bjc.6603536
Powles T, Young A, Sanitt A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al.(2006). The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours. Br J Cancer vol. 95, (9) 1145-1147.
10.1038/sj.bjc.6603416
Powles T, Macdonald D, Nelson M, Stebbing J(2006). Hepatocellular cancer in HIV-infected individuals: tomorrow's problem?. EXPERT REV ANTICANC vol. 6, (11) 1553-1558.
10.1586/14737140.6.11.1553
Powles T, Oliver T, Bower M(2006). Non-AIDS-defining cancers in people with HIV infection: a sleeping giant?. J HIV Ther vol. 11, (3) 57-60.
Stebbing J, Powles T, Nelson M, Bower M(2006). Significance of variation within HIV, EBV, and KSHV subtypes. Journal of the International Association of Physicians in AIDS Care vol. 5, (3) 93-102.
10.1177/1545109706290171
Bower M, Powles T, Nelson M, Mandalia S, Gazzard B, Stebbing J(2006). Highly active antiretroviral therapy and human immunodeficiency virus - Associated primary cerebral lymphoma. Journal of the National Cancer Institute vol. 98, (15) 1088-1091.
10.1093/jnci/djj302
Powles T, Young A, Short D, Savage P, Pappin C, Schmid P, Seckl M (2006). The outcome of patients with relapsed gestational trophoblastic neoplasm (GTN) after the completion of chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. vol. 24, 263S-263S.
Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, Bower M(2006). A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy. Lancet vol. 367, (9521) 1495-1502.
10.1016/S0140-6736(06)68649-2
Liu WM, Powles TB(2006). Cannabinoids: Do they have a role in cancer therapy?. LETT DRUG DES DISCOV vol. 3, (2) 76-82.
10.2174/157018006775789676
Powles T, Savage P, Short D, Young A, Pappin C, Seckl MJ(2006). Residual lung lesions after completion of chemotherapy for gestational trophoblastic neoplasia: should we operate?. BRIT J CANCER vol. 94, (1) 51-54.
10.1038/sj.bjc.6602899
Liu WM, Baird R, Sarker D, Powles T(2005). Antiapoptotic effect of growth factors in leukemia [1]. Journal of Clinical Oncology vol. 23, (3)
10.1200/JCO.2005.05.250
Bhardwa JM, Powles T, Berney D, Baithun S, Nargund VH, Oliver RTD(2005). Assessing the size and stage of testicular germ cell tumours: 1984-2003. BJU Int vol. 96, (6) 819-821.
10.1111/j.1464-410X.2005.05748.x
Waterston AM, Gumbrell L, Bratt T, Waller S, Gustav-Aspland J, L'Hermenier C, Bellenger K, Campbell M et al.(2005). Phase I study of TNFα AutoVaccine in Patients with metastatic cancer. Cancer Immunology, Immunotherapy vol. 54, (9) 848-857.
10.1007/s00262-005-0661-x
Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, Dhillon T, Young AM, Powles T et al.(2005). A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Annals of Internal Medicine vol. 143, (4)
10.7326/0003-4819-143-4-200508160-00007
Shamash J, Powles T, Mutsangwa K, Cotton L, Oliver T (2005). A phase II study of irinotecan, paclitaxel and oxaliplatin (IPO) in patients with multiply relapsed germ cell tumours (GCT). JOURNAL OF CLINICAL ONCOLOGY. vol. 23, 384S-384S.
Powles TB, Bhardwa J, Shamash J, Mandalia S, Oliver T(2005). The changing presentation of germ cell tumours of the testis between 1983 and 2002. BJU INT vol. 95, (9) 1197-1200.
10.1111/j.1464-410X.2005.05504.x
Berney DM, Argyle K, Cheang M, Powles T, Oliver RTD (2005). Erythropoietin and erythropoietin receptor expression in renal cell carcinomas. JOURNAL OF PATHOLOGY. vol. 205, 14-14.
Bower M, Powles T, Stebbing J, Thirlwell C(2005). Potential antiretroviral drug interactions with cyclophosphamide, doxorubicin, and etoposide [10]. Journal of Clinical Oncology vol. 23, (6) 1328-1329.
10.1200/JCO.2005.05.128
Shamash J, Powles T, Wilson P, Ansell W, Oliver T(2005). Prognostic factors in cytokine-refractory renal cell carcinoma treated with irinotecan, cisplatin, and mitomycin chemotherapy. J CLIN ONCOL vol. 23, (6) 1323-1325.
10.1200/JCO.2005.05.107
Powles T, te Poele R, Shamash J, Chaplin T, Propper D, Joel S, Oliver T, Liu WM(2005). Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood vol. 105, (3) 1214-1221.
10.1182/blood-2004-03-1182
Bower M, Powles T, Newsom-Davis T, Thirlwell C, Stebbing J, Mandalia S, Nelson M, Gazzard B(2004). HIV-associated anal cancer: Has highly active antiretroviral therapy reduced the incidence or improved the outcome?. Journal of Acquired Immune Deficiency Syndromes vol. 37, (5) 1563-1565.
10.1097/00126334-200412150-00004
Marvin V, Stebbing J, Powles T, Bower M(2004). The pharmacogenomics of anti-cancer chemotherapy. Minerva Biotecnologica vol. 16, (3) 181-188.
Oliver T, Shamash J, Powles T, Somasundram U (2004). 20 year phase 1/2 study of single agent carboplatin in metastatic seminoma: Could it have been accelerated by 72 hr PET scan response?. JOURNAL OF CLINICAL ONCOLOGY. vol. 22, 447S-447S.
Powles T, Shamash J, Ong J, MacDonald D, Kyle F, Palmiera C, Moller H, Oliver T (2004). The rising incidence of stage I seminoma; a reflection of earlier diagnosis of germ cell cancer of the testis in last 20 years. JOURNAL OF CLINICAL ONCOLOGY. vol. 22, 387S-387S.
Powles T, Bower M, Shamash J, Stebbing J, Ong J, Daugaard G, De Ruiter A, Johnson M et al.(2004). Outcome of patients with HIV-related germ cell tumours: a case-control study. BRIT J CANCER vol. 90, (8) 1526-1530.
10.1038/sj.bjc.6601762
Powles T, Powles J, Nelson M, Sandison A, Peston D, Buchannan J, Mandalia S, Gazzard B et al.(2004). Head and neck cancer in patients with human immunodeficiency virus-1 infection: incidence, outcome and association with Epstein-Barr virus. J LARYNGOL OTOL vol. 118, (3) 207-212.
10.1258/002221504322927982
Liu WM, Powles T, Shamash J, Propper D, Oliver T, Joel S(2004). Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene vol. 23, (4) 981-990.
10.1038/sj.onc.1207294
Powles T, Shamash J, Liu W(2004). Erythropoietin to treat anaemia in patients with head and neck cancer. LANCET vol. 363, (9402) 82-82.
10.1016/S0140-6736(03)15189-6
Kaanders JHAM, Van Der Kogel AJ, Haddad R, Posner M, Leyland-Jones B, Mahmud S, Blumberg N, Heal JM et al.(2004). Erythropoietin to treat anaemia in patients with head and neck cancer [2] (multiple letters). Lancet vol. 363, (9402) 78-79.
10.1016/S0140-6736(03)15183-5
Powles T, Bower M(2004). HIV and the risk of lung cancer. Journal of Clinical Oncology vol. 22, (7) 1348-1349.
10.1200/JCO.2004.99.265
Stebbing J, Wildfire A, Portsmouth S, Powles T, Thirlwell C, Hewitt P, Nelson M, Patterson S et al.(2003). Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: Clinical and angiogenic correlations. Annals of Oncology vol. 14, (11) 1660-1666.
10.1093/annonc/mdg461
Powles T, Nelson M, Bower M(2003). HIV-related lung cancer - A growing concern?. International Journal of STD and AIDS vol. 14, (10) 647-651.
10.1258/095646203322387875
Powles T, Shamash J, Berney D, Oliver RTD(2003). Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. BRIT J CANCER vol. 89, (6) 1140-1141.
10.1038/sj.bjc.6601176
Powles T, Thirwell C, Newsom-Davis T, Nelson M, Shah P, Cox S, Gazzard B, Bower M(2003). Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART?. British Journal of Cancer vol. 89, (3) 457-459.
10.1038/sj.bjc.6601111
Powles T, Thirlwell C, Nelson M, Bower M(2003). Immune reconstitution inflammatory syndrome mimicking relapse of AIDS related lymphoma in patients with HIV 1 infection. Leukemia and Lymphoma vol. 44, (8) 1417-1419.
10.1080/1042819031000083280
Powles T, Liu W, Shamash J, Oliver T, Joel S (2003). The effect of recombinant erythropoeitin on renal cancer cell lines and its role in chemosensitivity. BRITISH JOURNAL OF CANCER. vol. 88, S66-S66.
Powles T, Shamash J, Joel S, Oliver T, Liu W (2003). The role of CB1 and CB2 receptors in cannabis induced apoptosis in vitro. BRITISH JOURNAL OF CANCER. vol. 88, S25-S25.
Powles T, Bower M, Daugaard G, Shamash J, De Ruiter A, Johnson M, Fisher M, Anderson J et al.(2003). Multicenter study of human immunodeficiency virus-related germ cell tumors. J CLIN ONCOL vol. 21, (10) 1922-1927.
10.1200/JCO.2003.09.107
Bower M, Powles T, Nelson M, Shah P, Cox S, Mandelia S, Gazzard B(2003). HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS vol. 17, (3) 371-375.
10.1097/00002030-200302140-00011
Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P(2003). Overview of the main outcomes in breast-cancer prevention trials. Lancet vol. 361, (9354) 296-300.
10.1016/S0140-6736(03)12342-2
Powles T, Nelson M, Bower M(2003). HIV-related testicular cancer. International Journal of STD and AIDS vol. 14, (1) 24-27.
10.1258/095646203321043219
Powles T, Daugaard G, Nelson M, Oliver T, Fisher M, Stebbing J, Johnson M, Gazzard B et al.(2002). Multi-centre cohort study of testicular, cancer in men with HIV. BRIT J CANCER vol. 86, S19-S19.
Powles T, Imami N, Nelson M, Gazzard BG, Bower M(2002). Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS vol. 16, (4) 531-536.
10.1097/00002030-200203080-00003
Powles T, Bower M, Nelson M, Oliver RTD (2002). HIV related testicular cancer. GERM CELL TUMOURS V. Editors: Harden, P, Joffe, JK, Jones, WG, 51-52.
Powles T, Matthews G, Bower M(2000). AIDS related systemic non-Hodgkin's lymphoma. Sexually Transmitted Infections vol. 76, (5) 335-341.
10.1136/sti.76.5.335
Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG(2000). Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood vol. 96, (8) 2730-2734.
Powles T, Bower M(2000). HIV-associated Hodgkin's disease. International Journal of STD and AIDS vol. 11, (8) 492-494.
10.1258/0956462001916362
Gill J, Powles T, Bower M(2000). The molecular genetics of human herpesvirus 8. Hospital Medicine vol. 61, (5) 306-309.
10.12968/hosp.2000.61.5.1327
Return to top